Validação da LAP1B como nova proteína reguladora da proteína fosfatase 1 by Graça, Mariana Santos Moreda
  
 
Universidade de Aveiro 
2009  
Departamento de Biologia 
MARIANA SANTOS 
MOREDA GRAÇA 
 
 
VALIDAÇÃO DA LAP1B COMO NOVA PROTEÍNA 
REGULADORA DA PROTEÍNA FOSFATASE 1 
 
VALIDATION OF LAP1B AS A NOVEL PROTEIN 
PHOSPHATASE 1 REGULATOR 
 
 
 
   
  
  
 
Universidade de Aveiro 
2009  
Departamento Biologia  
MARIANA SANTOS 
MOREDA GRAÇA 
 
 
VALIDAÇÃO DA LAP1B COMO NOVA PROTEÍNA 
REGULADORA DA PROTEÍNA FOSFATASE 1 
 
VALIDATION OF LAP1B AS A NOVEL PROTEIN 
PHOSPHATASE 1 REGULATOR 
 
  
Dissertação apresentada à Universidade de Aveiro para cumprimento dos 
requisitos necessários à obtenção do grau de Mestre em Biologia Molecular e 
Celular, realizada sob a orientação científica do Professor Doutor Edgar Cruz e 
Silva, Professor Associado do Departamento de Biologia da Universidade de 
Aveiro, e co-orientação da Professora Doutora Sandra Rebelo, Professora 
Auxiliar Convidada da Secção Autónoma de Ciências da Saúde da 
Universidade de Aveiro. 
 
  
  
  
 
 
 
 
 
 
o júri   
 
presidente Professora Doutora Maria de Lourdes Gomes Pereira 
Professora Associada com Agregação da Universidade de Aveiro  
  
 
Professor Doutor Edgar Figueiredo da Cruz e Silva 
Professor Associado da Universidade de Aveiro 
  
  
Professora Doutora Sandra Maria Tavares da Costa Rebelo 
Professora Auxiliar Convidada da Universidade de Aveiro 
  
  
Doutor Michael Schrader 
Investigador Principal do Centro de Biologia Celular da Universidade de Aveiro 
  
  
 
  
  
 
  
  
 
  
  
  
 
 
  
  
 
agradecimentos 
 
Ao Professor Edgar Cruz e Silva e à Professora Odete Cruz e Silva pela 
oportunidade trabalhar no Laboratório de Transdução de Sinais e no 
Laboratório de Neurociências, respectivamente.  
 
Ao Professor Edgar Cruz e Silva pela orientação e pelos conhecimentos 
partilhados que permitiram o desenvolvimento da tese. 
 
À Sandra Rebelo pela ajuda, disponibilidade e orientação da tese. 
 
A todos os colegas do Laboratório de Neurociências e do Laboratório de 
Transdução de Sinais que sempre se disponibilizaram para ajudar. 
 
Aos meus pais e à minha irmã por todo o apoio. 
 
Aos meus amigos que estiveram sempre presentes. 
   
  
  
 
 
 
 
 
 
 
 
 
 
  
palavras-chave 
 
Fosforilação de proteínas, proteína fosfatase 1 (PP1), proteína 1B associada 
com a lâmina (LAP1B), torsinaA, distonia de torção de incidência precoce 
(DTIP). 
 
 
resumo 
 
 
A proteína fosfatase 1 (PP1) é uma proteína fosfatase específica para a 
desfosforilação de resíduos de serina e treonina que apresenta elevados níveis 
de expressão no cérebro. A PP1 participa na regulação de diversos processos 
celulares através da ligação a outras subunidades proteicas responsáveis pela 
sua especificidade e actividade. No rastreio de uma biblioteca de cDNA de 
cérebro humano, pelo método dois híbrido de levedura utilizando as isoformas 
da PP1 como isco, a proteína 1B associada com a lâmina (LAP1B) foi 
identificada como uma nova potencial proteína reguladora da PP1. A função da 
LAP1B não é totalmente conhecida, mas sabe-se que é uma proteína da 
membrana interna do núcleo que interage com as lâminas nucleares e com a 
proteína torsinaA, a qual está envolvida na distonia de torção de incidência 
precoce (DTIP). A LAP1B apresenta três motivos potenciais de ligação à PP1, 
um motivo SILK (um segundo motivo genérico de ligação à PP1) e diversos 
locais de fosforilação. Dado isto, a interacção entre a PP1 e a LAP1B foi 
confirmada por meio de várias técnicas. Por co-transformação em levedura, a 
interacção entre a LAP1B e as isoformas alfa (α), gama1 (γ1) e gama2 (γ2) da 
PP1 foi confirmada e, além disso, ficou demonstrado que a LAP1B interage 
com a PP1γ1 através do domínio de ligação 1 (BM1, REVRF). Este domínio 
está localizado na porção nucleoplásmica da LAP1B. O ensaio de blot overlay, 
utilizando a PP1γ1 purificada, permitiu comprovar in vitro a interacção entre a 
PP1 e a LAP1B através da porção nucleoplásmica da LAP1B. A interacção 
PP1/LAP1B foi comprovada in vivo por co-imunoprecipitação utilizando 
anticorpos específicos e por co-localização entre a LAP1B e a PP1γ e a PP1α, 
a qual foi verificada em estruturas subnucleares ainda não identificadas e em 
alguns pontos próximos do invólucro nuclear. O papel funcional do complexo 
PP1/LAP1B não foi determinado, mas pode ser importante na estrutura nuclear 
durante a mitose. Tendo em conta os elevados níveis de expressão da PP1 no 
estriado e a relação entre o sistema dopaminérgico dos núcleos basais e a 
DITC, a existência de um putativo tricomplexo PP1/LAP1B/torsinaA e a 
hipótese da PP1 e/ou a anormal fosforilação de proteínas ter um papel na 
DITC merece ser investigada. 
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abstract 
 
Protein phosphatase 1 (PP1) is a ubiquitously expressed serine/threonine 
protein phosphatase, with high expression levels in brain. PP1 regulates many 
cellular processes through interaction with different regulatory subunits that 
play regulatory and targeting roles. From yeast two-hybrid screens of a human 
brain cDNA library using PP1 isoforms as bait, lamina associated polypeptide 
1B (LAP1B) was identified as a novel putative PP1 regulator. The functional 
role of LAP1B is poorly understood, but it is known that LAP1B is an inner 
nuclear membrane protein that interacts with lamins and torsinA, a protein 
involved in early onset torsion dystonia (EOTD). Furthermore, LAP1B has three 
potential PP1 binding motifs, a second generic PP1 binding motif named SILK 
and several phosphorylation sites. Thereby, we confirmed the PP1/LAP1B 
interaction by a variety of techniques. By yeast co-transformation we confirmed 
the interaction of LAP1B with PP1 isoforms alpha (α), gamma1 (γ1) and 
gamma2 (γ2) and demonstrated that LAP1B interacts with PP1γ1 through 
binding motif 1 (BM1, REVRF) that is located in the nucleoplasmic portion of 
LAP1B. The PP1/LAP1B interaction through the nucleoplasmic portion of 
LAP1B was also confirmed in vitro by blot overlay assay with purified PP1γ1 
protein. The PP1/LAP1B interaction in vivo was evaluated by co-
immunoprecipitation with specific antibodies and by co-localization between 
LAP1B and PP1α and PP1γ, ocurring at subnuclear structures and at locations 
near the nuclear envelope. The functional role of PP1/LAP1B complex was not 
determinated but it may be important in the maintenance of the nuclear 
architecture during mitosis. Given the high expression levels of PP1 within 
striatum and the relationship between basal ganglia dopaminergic signalling 
and EOTD, the existence of a putative tricomplex PP1/LAP1B/torsinA  and the 
hypothesis that PP1 and/or abnormal protein phosphorylation may have a role 
in EOTD should be worthwhile exploring. 
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Abbreviations 
 
aa Amino acid 
AAA
+
 ATPases ATPases associated with various cellular activities 
AD Alzheimer’s disease 
Ade Adenine 
ADP Adenosine diphosphate 
Ala  Alanine  
APS Ammonium persulfate 
ATP Adenosine triphosphate 
AKAP-149 A-kinase-anchoring protein 149 
APP Amyloid precursor protein 
Asn Asparagine 
BCA Bicinchoninic acid 
BM Binding motif 
BSA Bovine serum albumin 
cDNA Complementary deoxyribonucleic acid 
CK Casein Kinase 
DAPI 4',6-diamidino-2-phenylindole 
DARPP-32 Dopamine and cAMP-regulated phosphoprotein 
DAT Dopamine transporter 
DNA Deoxyribonucleic acid 
DOPAC 3,4-dihydroxyphenylacetic acid 
ECL Enhanced Chemiluminescence 
ER Endoplasmic reticulum 
EOTD Early onset torsion dystonia 
FITC Fluorescein isothiocyanate 
GAL4 Gal4 transcription factor 
GAL4-AD Gal4 activation domain 
GAL4-BD Gal4 DNA binding domain 
GSK3 Glycogen synthetase kinase 3 
His Histidine 
HVA Homovallinic acid 
INM Inner nuclear membrane 
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IP Immunoprecipitation  
IPTG Isopropyl-β-D-thiogalactopyranoside 
KLC Kinesin light chain 
LAP Lamina associated protein 
LB Loading buffer 
LB medium Luria-Bertani medium 
LBR Lamin B receptor 
LGB Lower gel buffer 
LiAc Lithium acetate 
Leu Leucine 
mRNA Messenger ribonucleic acid  
NE Nuclear envelope 
NIPP1 Nuclear inhibitor of PP1 
NLS Nuclear localization signal 
NRBOX Nuclear receptor box 
OD Optical density 
ONM Outer nuclear membrane 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEI Polyethylenimine 
PLK Polo-like kinase 
PP1 Protein phosphatase 1 
PP2A Protein phosphatase 2A 
PP1c Protein phosphatase 1 catalytic subunit 
PPM Metal ion dependent protein phosphatase 
PPP Phosphoprotein phosphatase 
PTP Tyrosine protein phosphatase  
QDO Quadruple dropout 
RNA Ribonucleic acid 
rpm Rotation per  minute 
SD Supplement dropout medium 
SDS Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate – polyacrylamide gel electrophoresis 
SP Signal peptide 
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SIPP1 Splicing factor that interacts with PQBP-1 and PP1 
SUMO-1 Small ubiquitin-like modifier-1 
TBS Tris-buffered saline solution 
TBST TBS supplemented with Tween detergent 
TDO Triple dropout 
TEMED N,N,N',N'-Tetramethylethylenediamine 
TM Transmembrane domain 
TOR1AIP1 TorsinA interacting protein 1 
TPR Tetratricopeptide repeat 
Trp Tryptophan 
UAS Upstream activating sequence 
UGB Upper gel buffer 
ULM UHM ligand motif 
Val Valine  
VMAT2 Vesicular monoamine transporter 2 
Wt Wild type 
YPD Yeast Peptone Dextrose 
YTH Yeast two-hybrid 
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1.1. Protein phosphorylation 
 
Reversible protein phosphorylation is a major mechanism for controlling 
intracellular events in eukaryotic cells. Cellular health and vitality are dependent on the 
fine equilibrium of protein phosphorylation systems (1). Reversible protein 
phosphorylation involves either the addition of phosphate groups via the transference of 
the terminal phosphate from ATP to an amino acid residue by protein kinases or its 
removal by protein phosphatases (Fig. 1). This post-translational modification can have 
profound effects on the activities and properties of various proteins.  
 
 
Figure 1. Schematic representation of reversible protein phosphorylation. Protein kinases transfer a 
phosphate group from ATP to a target protein (protein phosphorylation), while protein phosphatases catalyze 
the hydrolysis of the phosphate group from the target protein (protein dephosphorylation). 
 
 
Protein phosphorylation regulates several processes like the metabolism, 
contractility, membrane transport and secretion, the transcription and translation of genes, 
cell division, fertilization and memory (reviewed in 1). Additionally, various diseases, like 
neurodegenerative diseases and diabetes, are associated with abnormal phosphorylation of 
specific proteins. In Alzheimer’s disease (AD) there is evidence for abnormal regulation of 
protein phosphorylation. AD is characterized mainly by the presence of neuritic plaques 
and neurofibrillary tangles in the brains of affected individuals. Neurofibrillary tangles 
result from the aggregation of abnormally phosphorylated Tau protein into paired helical 
filaments. Glycogen synthase kinase 3 β and protein kinase A may be key kinases involved 
 Validation of LAP1B as a novel PP1 regulator 
 
Mestrado em Biologia Molecular e Celular 15 
 
in Tau phosphorylation (2), with protein phosphatase 2A (PP2A) and protein phosphatase 
1 (PP1) being responsible for tau hyperphosphorylation (3, 4). Moreover, the inactivation 
of PP1 leads to a relative increase in the utilization of the non-amyloidogenic pathway for 
Alzheimer’s amyloid precursor protein (APP) processing (5). Other neurodegenerative 
diseases associated with abnormal protein phosphorylation are Parkinson’s disease and 
Huntington’s disease. Lewy bodies (proteinaceous inclusions) are one of the pathological 
features of Parkinson’s disease and the polypeptide α-synuclein was found to be a major 
constituent of Lewy bodies. Protein phosphorylation may have a role in the regulation of α-
synuclein. It was demonstrated that α-synuclein is constitutively phosphorylated, 
predominantly on serine residues (6). Huntington’s disease is characterized by motor and 
cognitive deficits probably caused by progressive and neuronal dysfunction preceding 
neuronal cell death. Synapsin I is considered one of the major phosphoproteins with 
importance in regulating of neurotransmitter release. Synapsin I is abnormally 
phosphorylated in mice expressing the Huntington’s disease mutation and it has been 
suggested that an inbalance between kinase and phosphatase activities also occurs in 
Huntington’s disease (7). 
About one-third of all eukaryotic proteins are controlled by protein phosphorylation 
of specific tyrosine, serine and threonine residues. The protein phosphorylation (or 
dephosphorylation) of tyrosine, serine and threonine residues causes conformational 
changes in proteins modifying their biological properties. The reversible protein 
phosphorylation level of a protein reflects the balance between the activities of the protein 
kinases and phosphatases involved. Eukaryotic cells express various proteins kinases and 
phosphatases, which have specific substrates, cellular localizations and regulation 
mechanisms. Whereas the number of tyrosine phosphatases is approximately the same of 
tyrosine kinases, the number of serine/threonine kinases is much higher to that of 
serine/threonine phosphatases. However, the diversity of phosphatase interacting proteins 
is enormous, so the diversity of serine/threonine phosphatases is seen mainly at the 
holoenzyme level (8, 9). Therefore, protein phosphorylation systems represent attractive 
targets for diagnostics and therapeutics of several diseases, like neurodegenerative diseases 
and others (10). 
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1.2. Protein phosphatases 
 
Protein phosphatases belong to three unrelated gene families: the PPM family 
(metal ion dependent protein phosphatases), the PTP family (tyrosine protein 
phosphatases) and the PPP family (phosphoprotein phosphatases). Members of PPP family 
are responsible for desphosphorylation of serine/threonine residues and are divided in the 
following subfamilies: PP1, PP2A, Protein Phosphatase 4 (PP4), Protein Phosphatase 6 
(PP6), Protein Phosphatase 2B (PP2B), Protein Phosphatase 5 (PP5) and Protein 
Phosphatase 7 (PP7) (8, 11, 12). The remarkable degree of evolutionary conservation of 
these enzymes (Fig. 2) is related to their essential role in the regulation of fundamental 
cellular processes (13, 14). Among the serine/threonine protein phosphatases, PP1 forms a 
major class and is highly conserved among all eukaryotes examined to date (15). 
 
 
Figure 2. Phylogenic tree representing the similarity between the known members of the phosphoprotein 
phosphatase (PPP) family based on their primary amino acid sequence (adapted from 16).  
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1.2.1.  Protein Phosphatase 1 (PP1) 
 
PP1 is the most widely expressed and abundant protein serine/threonine 
phosphatase which regulates a variety of cellular functions (17). PP1 is involved in 
glycogen metabolism, transcription, protein synthesis, cellular division and meiosis, and 
apoptosis. When nutrients are abundant PP1 stimulates the synthesis of glycogen and also 
enables the return to the basal state of protein synthesis and the recycling of transcription 
and splicing factors. PP1 is required for anaphase progression, exit from mitosis and is also 
responsible for maintenance of the cells in G1 or G2 cell cycle phases. In addition, PP1 can 
also promote apoptosis when cells are damaged (reviewed in 8).  
PP1 holoenzymes are composed by a highly conserved catalytic subunit called 
protein phosphatase 1 catalytic subunit (PP1c) and one or two variable regulatory subunits. 
Interestingly, the catalytic subunit of PP1 has multiple points of interaction with a 
regulatory subunit (Fig. 3), with the latter being responsible for the targeting of PP1 to a 
particular subcellular compartment and also determining its substrate specificity and 
activity. These regulatory subunits can be substrates that directly associate with PP1c, 
substrate specifiers and/or targeting proteins (9, 17). The inhibitors like inhibitor-1 (18), 
for example, in their phosphorylated form, block the activity of PP1c towards all 
substrates. I1
PP2A
/PHAP-II (19), is a substrate specifier that promotes the 
dephosphorylation of specific substrates by PP1c. Spinophilin is a targeting subunit for 
PP1 (20), which directs PP1 to dendritic spines in brain. PP1 regulates several cellular 
functions through the interaction of its catalytic subunit with the different regulatory 
subunits (14).  
 
 
 
Figure 3. Schematic representation of the PP1 holoenzyme structure. The protein phosphatase 1 catalytic 
subunit (PP1c) interacts with a regulatory subunit (R subunit) which often brings the holoenzyme to 
proximity of its substrates. Hormones and metabolites can modulate PP1 interactions (adapted from 9). 
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Most PP1 binding proteins interact with the PP1 catalytic subunit through a 
conserved PP1 binding motif termed the RVxF motif which have the consensus (R/K) 
XA(0-1) (V/I) XB (F/W) sequence, where Xa is any amino acid and XB is any amino acid 
except proline (9, 21). The binding of the RVxF motif to PP1c does not cause major 
conformational changes of PP1, and no significant effect on its catalytic activity (22). 
However, the RVxF motif mediate the initial anchoring of regulatory subunits to PP1 and 
thereby promotes the occupation of secondary and lower affinity binding sites, and this 
often does affect the activity and/or substrate specificity of PP1 (9, 21). Recently, a second 
generic PP1-binding motif was identified and is called the SILK-motif: [GS]-IL-[KR] (23). 
The SILK motif was first described for inhibitor-2 (24), a specific PP1 inhibitor, and can 
functionally replace the RVxF motif in NIPP1 (21). The existence of these conserved 
binding sites within regulatory subunits explains why a relatively small protein such as 
PP1c can interact with numerous different regulatory proteins and why the binding of most 
regulatory subunits is mutually exclusive (9). Since the regulatory subunits are responsible 
for controlling PP1 activity, the key to understanding PP1 function lies in studying the 
cellular functions of these subunits (25).  
PP1 is expressed in mammalian cells in three isoforms: PP1alpha (α), PP1gamma 
(γ) and PP1Beta/Delta (β/δ), which are encoded by distinct genes (26-28). These isoforms 
are about 90% identical in amino acid sequence; most of the differences are located on the 
N and C terminals (Fig. 4). The gene encoding PP1γ undergoes alternative splicing to 
originate a ubiquitous PP1gamma 1 (PP1γ1) variant and a PP1gamma 2 (PP1γ2) variant 
enriched in testis (26, 29). 
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PP1gamma1       MADLDKLNIDSIIQRLLEVRGSKPGKNVQLQENEIRGLCLKSREIFLSQPILLELEAPLK 60 
PP1gamma2       MADLDKLNIDSIIQRLLEVRGSKPGKNVQLQENEIRGLCLKSREIFLSQPILLELEAPLK 60 
PP1alpha        MSDSEKLNLDSIIGRLLEVQGSRPGKNVQLTENEIRGLCLKSREIFLSQPILLELEAPLK 60 
PP1beta         MADG-ELNVDSLITRLLEVRGCRPGKIVQMTEAEVRGLCIKSREIFLSQPILLELEAPLK 59 
                *:*  :**:**:* *****:*.:*** **: * *:****:******************** 
 
PP1gamma1       ICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 120 
PP1gamma2       ICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 120 
PP1alpha        ICGDIHGQYYDLLRLFEYGGFPPESNYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 120 
PP1beta         ICGDIHGQYTDLLRLFEYGGFPPEANYLFLGDYVDRGKQSLETICLLLAYKIKYPENFFL 119 
                ********* **************:*********************************** 
 
PP1gamma1       LRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 180 
PP1gamma2       LRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 180 
PP1alpha        LRGNHECASINRIYGFYDECKRRYNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 180 
PP1beta         LRGNHECASINRIYGFYDECKRRFNIKLWKTFTDCFNCLPIAAIVDEKIFCCHGGLSPDL 179 
                ***********************:************************************ 
 
PP1gamma1       QSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVLGWGENDRGVSFTFGAEVVAKFLHKHD 240 
PP1gamma2       QSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVLGWGENDRGVSFTFGAEVVAKFLHKHD 240 
PP1alpha        QSMEQIRRIMRPTDVPDQGLLCDLLWSDPDKDVQGWGENDRGVSFTFGAEVVAKFLHKHD 240 
PP1beta         QSMEQIRRIMRPTDVPDTGLLCDLLWSDPDKDVQGWGENDRGVSFTFGADVVSKFLNRHD 239 
                ***************** *************** ***************:**:***::** 
 
PP1gamma1       LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPAE 300 
PP1gamma2       LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPAE 300 
PP1alpha        LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGAMMSVDETLMCSFQILKPAD 300 
PP1beta         LDLICRAHQVVEDGYEFFAKRQLVTLFSAPNYCGEFDNAGGMMSVDETLMCSFQILKPSE 299 
                ****************************************.*****************:: 
 
PP1gamma1       KKK---------PNATRPVTPPRG------MITKQAKK-------- 323 
PP1gamma2       KKK---------PNATRPVTPPRVGSGLNPSIQKASNYRNNTVLYE 337 
PP1alpha        KNKGKYGQFSGLNPGGRPITPPRN-------SAKAKK--------- 330 
PP1beta         KKAKYQYG---GLNSGRPVTPPRT--------ANPPKKR------- 327 
 
Figure 4. Analysis of homology of PP1 isoforms using a CLUSTAL W multiple sequence alignment. 
 
 
The subcellular localization of endogenous PP1 isoforms is not entirely clear. 
Although the three isoforms can be found in the nucleus and cytoplasm, they exhibit some 
differences in intranuclear distribution. PP1α is diffusely distributed in the cytoplasm and 
in the nucleoplasm and is excluded from the nucleolus. PP1γ has diffuse distribution in the 
cytoplasm and nucleoplasm and accumulates in nucleoli with a pattern corresponding to 
the granular compartment that contains ribosomal RNA. PP1β/δ is also diffuse in 
cytoplasm and nuclei and localizes in nucleoli, but not to the same extent as PP1γ. 
Different subcellular localization of PP1 isoforms can be due to different affinities for 
regulatory subunits which have distinct subcellular distribution themselves. Localization of 
a particular PP1 isoform can also change according to the level of expression of interacting 
subunits (30, 31). 
PP1α and PP1γ1 are ubiquitously expressed in mammalian tissues, with higher 
expression in brain. In brain, the mRNA for PP1α, PP1γ1 and also for PP1β/δ was found to 
be particularly abundant in hippocampus and cerebellum. At the protein level PP1α and 
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PP1γ1 have highest levels of expression in the striatum, where they were shown to be 
relatively enriched in the medium-sized spiny neurons. These neurons are also known to 
contain DARPP-32 (29) which is a PP1 inhibitor. In the neostriatum PP1 is involved in the 
action of several neurotransmitters, like dopamine and glutamate, via regulation by 
DARPP-32 (dopamine and cAMP-regulated phosphoprotein, Mr 32000 Da). Dopamine 
causes the phosphorylation and activation of DARP-32 by the increase of intracellular 
cAMP and by activation of protein kinase A (32). Glutamate causes the dephosphorylation 
and inactivation of DARPP-32 by increasing calcium levels and activating protein 
phosphatase 2B (33). Dopamine and the dopamine D1 receptor are also highly enriched in 
the neostriatum. Thus, it is believed that PP1 may play a role in dopaminergic signal 
transduction (34). Modifications of the normal action of these neurotransmitters contribute 
to the etiology of several neuropsychiatric disorders. At the ultrastructural level, PP1α and 
PP1γ1 immunoreactivity was demonstrated in dendritic spine heads and spine necks (34). 
PP1γ1 is highly and specifically concentrated in the post-synaptic density of these spines. 
Dendritic spines are the principal sites for excitatory synapses in the central nervous 
system, so neuronal signalling study focus on PP1α and PP1γ1 (35). Furthermore, 
spinophilin is a PP1 binding protein that is highly expressed in brain and within neurons 
and is enriched in dendritic spines (20). Another PP1 binding protein enriched in brain and 
particularly in dendritic spines is neurabin (36). Both spinophilin and neurabin bind actin 
(20, 37), and it was also demonstrated that PP1γ1 associates with actin. PP1α and PP1γ1 
bind to spinophilin and actin more avidly than PP1β (38, 39). These findings suggest that 
the dendritic spine localization of PP1γ1 (and PP1α) may result from binding of these 
phosphatases to neurabin and/or spinophilin (39).  
The higher expression levels of PP1 in brain indicate that possibly it has an 
important role in the control of several brain functions. For instance, a role for PP1 in 
memory and learning has been outlined. Inhibition of PP1 in vivo induces deficits in 
memory retention and a role in age-related cognitive decline was proposed for PP1 (40). 
Additionally, PP1 is involved in AD. AD is characterized clinically by a progressive and 
irreversible decline of cognitive functions, and pathologically by the presence of neuritic 
plaques and neurofibrillary tangles. The cognitive decline seen in AD is thought to be 
related mainly with a decrease in synaptic contacts (41), where PP1 has an important role 
since it is enriched in dendritic spines.  
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PP1 is also involved in the maintenance of microtubule stability (42). Microtubules 
are a major cytoskeleton element in eukaryotic cells and have a crucial role in cell motility, 
division and differentiation. The microtubule motor protein kinesin plays an important role 
in intracellular mobility. Phosphorylation of kinesin light chain (KLC) is regulated by a 
kinase and by PP1, and the level of KLC phosphorylation is directly correlated with 
activation of kinesin motor activity (43). Tau is responsible for PP1 binding to 
microtubules, suggesting that tau is a PP1 targeting subunit. The association of PP1 with 
microtubules may lead to dephosphorylation of microtubule-associated proteins, like tau, 
which enhances their association with microtubules and promotes microtubule stability 
(42).  
 
 
 
1.3. TorsinA 
 
TorsinA and its related family members belong to the AAA
+
 superfamily of 
ATPases associated with several subcellular activities (44). Members of AAA
+
 ATPases 
are typically chaperone proteins that mediate conformational changes in target proteins. 
AAA
+
 ATPases use the energy of ATP binding and hydrolysis to induce conformational 
changes in their substrates. These proteins are involved in several functions: protein 
folding and degradation, membrane trafficking, DNA replication and repair and 
cytoskeletal regulation (45). The high conservation of the AAA
+
 ATPase family among 
species suggests an important role for torsinA in cell biology (46). TorsinA knockout 
mices die 48 hours after birth, indicating that torsinA plays an essential role on cellular 
function (47).  
A mutation in DYT1 (TOR1A) gene, which encodes human torsinA, is responsible 
for the movement disorder termed early onset torsion dystonia (EOTD) (44). Dystonias are 
a relatively rare class of neurologic disease. The term dystonia refers to pathological 
involuntary muscle contractions that induce repetitive and twisting movements, and 
abnormal posture. Early onset torsion dystonia (or Oppheim’s disease or DYT1 dystonia) 
is the most common and severe form of hereditary primary dystonia, and develops in 
childhood or adolescence. EOTD is an autosomal dominant disease with a penetrance of 
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30-40% (reviewed in 48). Most cases of this disease are associated with an in-frame 3bp 
deletion (∆GAG) in torsinA that removes one glutamic acid residue at position 302 or 303 
(∆E302/303), close to the C terminal of torsinA (44).  
Despite the absence of neuronal neurodegeneration in other organisms down-
regulation of torp4a, encoding the Drosophila homologue TorsinA, was shown to enhance 
neurodegeneration in retina of the flies (49). 
TorsinA is expressed in many tissues, with highest levels in liver, muscle, pancreas 
and brain (44). In brain, torsinA mRNA is expressed in all brain regions with higher levels 
in cerebral cortex, thalamus, hippocampus, striatum, substantia nigra pars compacta, 
cerebellum, midbrain pons and spinal cord (50-52). The highest expression was detected in 
the dopaminergic neurons of substantia nigra pars compacta (50, 51), suggesting a link 
between the basal ganglia dopaminergic system and EOTD (52-54).  
As a primary neurological characteristic, dystonia can be associated with 
neurodegenerative diseases like Parkinson disease. Parkinson disease is associated with 
progressive loss of dopaminergic neurons from the substantia nigra pars compacta. 
TorsinA is highly expressed in dopaminergic neurons and is a component of Lewy bodies 
(pathological feature of Parkinson disease), where it is associated with α-synuclein (55). In 
mice overexpressing mutant torsinA (∆GAG), dopamine and its metabolites, 3,4-
dihydroxyphenylacetic acid (DOPAC) and homovallinic acid (HVA) levels were altered 
(56). Coexpression of torsinA with DAT (dopamine transporter) in HEK293 cells 
decreased dopamine uptake as compared with cells expressing only DAT. Thus torsinA 
overexpression did not alter significantly the affinity of dopamine for DAT but it may 
interfere with DAT delivery to plasma membrane. As a consequence, it was observed that 
DAT levels at the plasma membrane are reduced in the presence of torsinA and it 
colocalizes with torsinA in intracellular compartments (57). Overexpression of torsinA and 
TOR-2 (TorsinA Caenorhabditis elegans homolog) in C. elegans dopaminergic neurons 
can lead to the suppression of neurodegeneration induced by 6-OHDA treatment. Animals 
expressing mutant torsinA (∆GAG) demonstrated reduced protection from 6-OHDA. 
Therefore, it was demonstrated that torsinA and TOR-2 may protect dopaminergic neurons 
from 6-OHDA through downregulating the expression of the dopamine transporter DAT-1 
in vivo. Additionally, it was demonstrated that torsinA and TOR-2 also protected 
dopaminergic neurodegeneration caused by overexpression of α-synuclein (58). 
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TorsinA is a 332 amino acid protein with potential sites of glycosylation and 
phosphorylation, as well as a putative membrane spanning domain (44) and a putative 
bipartite nuclear localization sequence (54). This protein contains a single ATP-binding 
AAA
+
 module, including Walker A and Walker B nucleotide binding motifs and α-helical 
domains, sensor 1 and sensor 2 (Fig. 5), which have been proposed to mediate substrate 
interactions and are critical for ATP hydrolysis. In the C-terminal region there is poor 
similarity between torsinA and other AAA
+
 proteins (59). This C-terminal region of 
torsinA (where ∆GAG deletion occurs) may contain a supposed binding domain, which 
determines the role of the protein (60). 
 
 
 
Figure 5. Schematic representation of torsinA protein and its characteristic domains. TorsinA is a 332 amino 
acid (aa) protein. The structure of torsinA was predicted to contain an amino-terminal signal peptide (SP) 
sequence which is removed from the mature protein, a putative transmembrane domain (TM) and a putative 
bipartite nuclear localization signal (NLS). Arrow indicates the signal peptide cleavage, which results in 
translocation of torsinA into the lumen of the endoplasmatic reticulum (ER). Walker A and Walker B are 
ATP binding sites and Sensor 1 and Sensor 2 are configurational domains of AAA
+
 ATPases. The ∆GAG 
mutation (∆E302E303) is located in sensor 2 region. TorsinA contains two sites for potential glycosylation (Asn 
143 and 158) (adapted from 61).  
 
 Validation of LAP1B as a novel PP1 regulator 
 
Mestrado em Biologia Molecular e Celular 24 
 
Some studies established that torsinA is a membrane-associated protein that faces 
the lumen of the endoplasmic reticulum (ER) (60, 62). In contrast Callan et al (63) 
demonstrated that torsinA does not behave as a typical integral membrane protein, since 
extraction at pH 11.3 is sufficient to completely remove torsinA from the ER membrane, 
but at pH 9.5 half of the protein remains associated with the membrane. Furthermore, it 
was suggested that signal peptidase complex cleaves the N-terminal signal peptide (Fig. 5) 
leading to full translocation of torsinA into de lumen of the ER. Consequently they 
conclude that torsinA is peripherally associated with the inner face of the ER membrane 
and this may be the result of binding to an integral membrane protein. ATP-free TorsinA is 
diffusely distributed throughout the ER, but if ATP is bound to torsinA, it is recruited to 
the nuclear envelope (NE) (64). Upon over-expression, wild type (Wt) torsinA was also 
found to be localized in the NE (64, 65) and mutant torsinA (∆GAG) showed redistribution 
to the NE. Furthermore, mutant torsinA colocalized with lamin B1 in the NE of neurons 
and there was almost no expression in the ER (65). Another study (66), which provides a 
quantitative analysis of the relative NE/ER distribution, demonstrated that dystonia-
associated mutations do not influence the localization of torsinA in non-neuronal cells 
(HeLa cells) in contrast with previous studies. However, dystonia-associated mutations 
were shown to induce translocation of torsinA from de ER to NE in neuronal cells (66). 
Abnormal accumulation of mutant torsinA (∆GAG) in the NE suggests that a NE 
dysfunction may contribute to EOTD pathogenesis (67). Interestingly, two torsinA binding 
proteins identified to date are integral membrane proteins: LULL1 in the ER and lamina 
associated polypeptide 1 (LAP1) in the nuclear envelope. Like torsinA, LAP1 and LULL1 
mRNAs are widely expressed in both neuronal and non-neuronal tissues (67). Increased 
expression of LULL1 was also found to change the localization of Wt torsinA and mutant 
torsinA from the ER to the nuclear envelope, suggesting a role for LULL1 in the 
distribution and activity of torsinA. Alterations in the activity of LAP1 or LULL1 may 
play a role in the pathogenesis of EOTD (68). Accumulation of mutant torsinA in the NE 
may alter the functions of NE interacting proteins, such as LAP1 and cause abnormality of 
the NE, including formation of blebs and herniations into the perinuclear space, which 
have been observed in cultured primary neurons from homozygous knock-out and knock-
in mice (47).  
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AAA
+
 ATPases frequently act as molecular chaperones and modulate protein-
protein interactions (45), so it was proposed that torsinA could modulate these interactions 
in the lumen of the perinuclear space. The interaction between transmembrane proteins of 
the inner and outer nuclear membrane can also be fundamental to the connection of nuclei 
with the cytoplasmic cytoskeleton (Fig. 6). TorsinA may regulate lumenal interactions 
between inner nuclear membrane (INM) and outer nuclear membrane (ONM) proteins 
(69).  
 
 
Figure 6. Schematic representation of the nuclear envelope (NE) and potential functions of torsinA. A- 
Schematic model of NE. The outer nuclear membrane (ONM) is morphologically continuous with the 
peripheral endoplasmatic reticulum (ER) and torsinA is relocalized from the (ER) to the NE. B- Model for 
association of cytoskeletal filaments with the NE. Cytoskeletal filaments may interact with the 
transmembrane proteins of the ONM and may associate with lamina associated polypeptides (LAPs) of the 
inner nuclear membrane (INM) via the lumenal domains. TorsinA may regulate lumenal interactions between 
the INM and the ONM proteins. NPC- Nuclear pore complex (69).  
 
 
TorsinA was also found associated with cytoskeletal elements like kinesin (70) and 
vimentin (71) (Fig. 7). The TPR (tetratricopeptide repeat) domain of the light chain subunit 
(KLC1) of kinesin-I interacts directly with the C-terminal region of torsinA. Wt torsinA 
and KLC1 have the same distribution in cytoplasm and processes of neural cells with 
enrichment at distal ends. Mutant torsinA was localized in cells bodies, in inclusions and 
often altered the distribution of kinesin that was then localized in these inclusions. This 
data support a possible role of torsinA in intracellular trafficking mediated by kinesin 
microtubules and possible etiology of EOTD (70). EOTD patients that do not develop 
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dystonic symptoms by age 28 are very unlikely to develop dystonia later. The age of 
vulnerability is associated with the period of motor learning in humans and with the 
developmental stage of high synaptic plasticity of neostriatum in primates (72) and rodents 
(73). An enrichment of kinesin and torsinA was found in growth cones of cultured rat 
cortical neurons. The interaction of kinesin and torsinA and their functional integrity could 
be required for active neurite outgrowth and/or synaptic plasticity, possibly associated with 
motor learning in the brain (70). Vimentin is an intermediate filament protein that 
associates with other cytoskeletal proteins such as kinesin, tubulin, actin and myosin. 
TorsinA was also found to associate with vimentin in fibroblasts. However, EOTD patient 
cells showed a decrease in the association of torsinA with the cytoskeletal elements. 
Immunoprecipitation of vimentin brings torsinA and other cytoskeletal proteins including 
kinesin and actin, suggesting a role for torsinA in their collective interaction (71). 
Additionally, another vimentin binding partner is LAP1B that interacts with torsinA at NE 
(67) and with vimentin and microtubules during mitosis (74). Nesprin-3, a protein of the 
outer nuclear membrane implicated in connecting the nucleus and cytoskeleton, is another 
NE protein that interacts with torsinA (75). 
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Figure 7. Schematic illustration of torsinA (TA) and mutant torsinA (∆GAG, ∆E) subcellular localization 
and potential roles. A- TorsinA is found in the endoplasmatic reticulum (ER) and nuclear envelope (NE), 
where its interacting proteins are shown. TorsinA is also associated with kinesin light chain 1 (KLC1) and 
binds snapin at the synapse. TorsinA may be involved in the localization of dopamine transporter (DAT) and 
may play a role in the correct function of vesicular monoamine transporter 2 (VMAT2). B- Cellular 
alterations caused by mutant torsinA (∆GAG). TorsinA and some factors controlling synaptic vesicles, 
including snapin and VMAT2, are recruited in perinuclear inclusions. The NE structure is abnormal and 
KLC1 function may be also affected. DA, dopamine; LAP1, lamina associated polypeptide 1; MT, 
microtubules (adapted from 61).   
 
 
Association of torsinA with the microtubule cytoskeleton was proposed to result 
from an indirect interaction through a protein partner. Additionally, torsinA was found to 
co-immunoprecipitate with the principal isoforms of tau in differentiated SH-SY5Y 
neuroblastoma cells. This association suggests that torsinA may modulate the interaction 
between tau and microtubules. SH-SY5Y cells express torsinA in both the cytoplasm and 
the perinuclear space. TorsinA distribution presents a punctate pattern, typical of 
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membrane associated proteins, and also a particular concentration at synaptic varicosities. 
Colocalization of torsinA and an integral vesicular protein synaptobrevin (VAMP), a 
marker of synaptic vesicles, was also demonstrated. Based on the localization of torsinA in 
the ER and colocalization of torsinA with synaptic vesicles markers, it was proposed that 
torsinA has a role in tubular-vesicular membrane trafficking along the neuronal processes. 
The association between torsinA, tau and microtubules is in apparent contrast with ER 
localization of torsinA. Nevertheless torsinA could be processed in the ER and then 
exported along the processes (76). More recently it was suggested that torsinA has a role in 
synaptic vesicle recycling. Snapin, a protein involved in vesicle exocytosis, and 
endogenous torsinA colocalize in dense core granules in PC12 cells, and was recruited to 
perinuclear inclusions (Fig. 7) containing mutant torsinA (∆GAG) in SH-SY5Y cells (77). 
Overexpression of mutant torsinA (∆GAG) also causes the entrapment of vesicular 
monoamine transporter 2 (VMAT2), a crucial regulator for dopamine levels, in 
membranous inclusions (78) (Fig. 7). 
 
 
 
1.4.Lamins and lamina associated polypeptides (LAPs) 
 
The NE is composed of an inner and outer nuclear membrane, the nuclear lamina 
and nuclear pore complexes. The ONM is continuous with the peripheral ER. The INM 
contains specific proteins that are not detected in the peripheral membrane and it is lined 
by the nuclear lamina (Fig. 8). The nuclear lamina is composed mainly by nuclear lamins 
that are proteins of the intermediate filament family. The nuclear lamina also contains 
peripheral and integral membrane proteins of the inner nuclear membrane (79, 80). The 
nuclear pore complexes are responsible for protein and nucleic acid movement to and from 
the nucleus. The perinuclear space is located between the INM and the ONM (Fig. 8) and 
is continuous with the ER (80). 
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Figure 8. Illustration of the nuclear membrane and proposed interactions between the nuclear lamina with 
inner nuclear membrane (INM) proteins, nuclear pores and other nucleoplasmic factors. The lamins are 
concentrated in the lamina and are also present in the nucleoplasm (red lines). The INM proteins include 
MAN1, lamin B receptor (LBR), ofetin, lamina associated polypeptide 1 and 2 (LAP1 and LAP2), emerin 
and nesprin. INM, inner nuclear membrane; ONM, outer nuclear membrane (adapted from 79). 
 
 
Lamins are classified as A-type or B-type lamins. The A-type lamins include lamin 
A, A∆10, C and C2; they are all encoded by the LMNA gene and are expressed in 
differentiated cells (81). The B-type lamins include lamin B, which is encoded by the 
LMNB1 gene, and lamin B2-B3 derived from the LMNB2 gene (82). These lamins are 
expressed in embryonic and somatic tissues. Originally, nuclear lamins were proposed to 
have a role in supporting the nuclear envelope and providing anchorage sites for 
chromatin, due to their position at the periphery of the inner nuclear membrane. More 
recently lamins were found in the nucleoplasm (Fig. 8), suggesting their involvement in 
nuclear envelope assembly, DNA synthesis, transcription and apoptosis. Thereby the 
nuclear lamina is disassembled during prophase/metaphase and this event is regulated by 
lamin phosphorylation. At telophase the lamins are dephosphorylated and the nuclear 
lamina is reassembled, approximately at the same time of nuclear envelope formation. The 
regulation of the lamin structures formed during nuclear envelope assembly may be 
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determined by the association of lamins with other proteins. These proteins can be integral 
proteins of the inner nuclear membrane or proteins that are not integral membrane 
components but are localized mostly in the region of the nuclear lamina. The first group, 
the INM proteins, include lamina associated proteins (LAPs), emerin, A-kinase-anchoring 
protein 149 (AKAP-149), lamin B receptor (LBR), MAN1, nesprin, otefin and others (79). 
INM proteins interact directly with nuclear lamina in vitro and remain associated with the 
nuclear lamina after extraction of the nuclei with non-ionic detergents, nucleases and/or 
high-salt buffers (83). The second group, proteins that are not integral INM proteins but are 
concentrated in the region of the nuclear lamina, include among others PP1 (84). PP1 has 
been implicated in lamin B dephosphorylation in late mitotic cells. It was proposed that 
PP1 mediates nuclear lamina reassembly, in part by dephosphorylation of lamin B (85). 
More recently, AKAP-149, identified as a component of the ER-nuclear system, was found 
to contain an RVxF motif that mediates interaction with PP1 (84). AKAP-149 recruits PP1 
to the NE upon NE assembly in vitro and promotes lamin B dephosphorylation and 
polymerization. At G1 phase, AKAP-149 anchors PP1 in the NE in proximity to lamin B 
and this complex is dissociated at the G1/S phase transition when serine phosphorylation of 
AKAP-149 occurs. Reassembly of the NE at the end of mitosis requires this association of 
PP1/lamin B to the nuclear envelope by AKAP-149 (86). 
 
 
 
1.4.1. Lamina associated polypeptide 1 (LAP1) 
 
Lamina associated polypeptides (LAPs) are type two INM proteins stably 
associated with the nuclear lamina. Lamina associated polypeptide 1 (LAP1) and lamina 
associated polypeptide 2 (LAP2) were identified by monoclonal antibodies generated 
against lamina-enriched fractions of rat liver nuclei (83, 87). LAP2 proteins are expressed 
in several isoforms that are derived from alternative splicing of the same gene and they are 
associated with type B lamins and mitotic chromosomes. LAP1 is expressed in three 
isoforms: LAP1A, LAP1B and LAP1C, which are, probably, splice products of one gene. 
Only the cDNA for LAP1C has been completely sequenced in rat, but partial 
characterization of other cDNAs suggested that the three LAP1 isoforms arise from 
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alternative splicing, since LAP1A and LAP1B cDNAs were identical to the LAP1C 
sequence with the addition of two insertions (88). In human, the sequences of LAP1A and 
LAP1C are only partially known and the full-length cDNA of human LAP1B was reported 
by Kondo et al (2002) (89). LAP1C was the most abundant LAP1 isoform found in a 
variety of cultured cells (87, 88).  
LAP1 isoforms have a large lumenal domain (Fig. 9) that has no homology with 
other type two proteins of the inner nuclear membrane (89). The transmembrane and the 
lumenal domains (Fig. 9) of LAP1 isoforms are encoded by a single exon, in rat, mouse 
and human. So, it is believed that LAP1 isoforms are different only in their nucleoplasmic 
portion (67). 
 
 
Figure 9. Schematic representation of LAP1 protein. Predicted nucleoplasmic and lumenal portions are 
represented as well the transmembrane domain (TM). INM- Inner nuclear membrane; ONM- Outer nuclear 
membrane (adapted from 67). 
 
 
LAPs are normally associated with type A and type B lamins, as well as mitotic 
chromosomes (83). During mitosis, LAP1C and lamin B colocalize in mitotic vesicles 
which associate transiently with the mitotic spindle (74). The function of LAP1 is poorly 
understood, but the interactions of LAPs with lamins and chromosomes may be important 
for maintenance of the nuclear architecture during interphase and mitosis (89). During 
mitosis, the ER undergoes disassembly to allow the partitioning of ER membranes to the 
daughter cells. In interphase LAP1 is localized in a nuclear rim, but during prometaphase 
LAP1 seems to be localized throughout the entire ER. In late anaphase, when nuclear 
envelope reassembles, LAP1 appeared to be concentrated in certain ER elements and is 
associated with chromosomes. Nuclear envelope membranes lose their identity as a distinct 
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subcompartment of the ER during mitosis and integral membrane proteins become 
dispersed throughout ER membranes. NE reassembly in late anaphase results from 
cooperative interactions between lamins, integral membrane proteins and chromossomes 
(90). LAP1 and LAP2 dissociate from the lamins at the onset of mitosis and associate 
before the reassembly of the nuclear lamin (83). 
Several INM proteins are involved in human diseases. Emerin mutations cause the 
X-linked form of Emery-Dreifuss Muscular Dystrophy, characterized by progressive 
weakness of the upper arms and lower limbs, and contractures of the elbows, Achilles 
tendon, neck and spine (91). LAP2α is associated with familial dilated cardiomyopathy and 
loss of LAP2α-lamin A binding was observed for the mutated protein in vitro (92). LBR 
mutations are associated with Pelget-Huet anomaly, characterized by abnormal nuclear 
shape and chromatin organization in blood granulocytes, and Greenberg’s skeletal 
dysplasia (93). MAN1 mutations cause Buschke-Ollendorff syndrome characterized by 
increased bone density (94). LAP1 has been identified as a torsinA interacting protein (67). 
As described previously, a mutation in torsinA is responsible for the autosomal movement 
disorder EOTD (44). TorsinA may interact with the conserved lumenal domain of LAP1. It 
was demonstrated that LAP1 recruits Wt torsinA to the NE in a perinuclear localization. 
These findings suggest that alterations in torsinA function may influence the nuclear 
lamina properties and that EOTD may cover abnormal molecular properties similar to that 
seen in diseases resulting from lamin mutations (67). 
 
 
 
1.5. Yeast two-hybrid system 
 
The yeast two-hybrid system is a method capable of detecting the interaction 
between two proteins via transcriptional activation of one or several reporter genes and is 
also used for searching for unknown partners (the prey) of a given protein (the bait) (Fig. 
10). This method is based on the properties of the yeast GAL4 protein, which has two 
separable domains, one responsible for DNA binding and another for transcriptional 
activation. The yeast two-hybrid assay is performed by expressing two fusion proteins in 
yeast. The first contains the GAL4 DNA binding domain (GAL4-BD) fused to a bait 
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protein and the other contain the GAL4 activation domain (GAL-AD) fused to a targeted 
protein (the prey) (95). The prey and bait constructs are introduced, by co-transformation 
or mating, into yeast strains containing the appropriate “Upstream Activating Sequence” 
(UAS) proximal to a reporter gene. When the bait and the target protein interact, the 
binding domain and the activation domain are brought together forming a functional 
transcriptional activator which leads to the transcriptional activation of the reporter gene 
(Fig. 10). Each Gal4 responsive gene contains a UAS target site. When Gal4 binds the 
UAS, transcription is activated from a downstream promoter. By linking the Gal4 UAS 
with other metabolic genes (e.g. ADE2, HIS3, MEL1 and lacZ) and by eliminating the wild 
type GAL4 gene, researchers have developed yeast strains that change phenotype when 
Gal4 is activated. Although the Gal4-BD can bind the UAS, it cannot activate transcription 
by itself. Transcription is activated only when the other half of the protein, Gal4-AD, joins 
the binding domain at the UAS. When performing a large scale screen, a plasmid library 
expressing cDNA-encoded GAL4-AD fusion proteins can be screened by introduction into 
a yeast strain. These larger scale yeast two-hybrid approaches typically rely on interaction 
by yeast mating (96, 97).  
 
 
Figure 10. General overview of the yeast two-hybrid system. The bait (PP1 in our experiments) is fused to 
the GAL4 DNA binding domain and the target protein (sequence from brain cDNA library) is fused to the 
activation domain. If the bait and prey interact, the GAL4 binding domain (BD) and the GAL4 activation 
domain (AD) are brought together forming a functional transcriptional activator which leads to the 
transcriptional activation of a downstream reporter gene (adapted from 98). 
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The advantages of this method are that it is simple, requires little optimization, is 
relatively inexpensive and is able to detect protein interactions in vivo. This method can 
generate false positives, however, high stringency media is used to prevent it. Even though 
two proteins can interact, it is not certain that they will also interact under physiological 
conditions. Therefore, the biological relevance of the proteins identified must always be 
confirmed using alternative methodology (98).  
In order to identify potential PP1 interacting and regulating proteins, and to 
characterize the PP1 human brain interactome, a large scale screen for PP1 binding 
proteins was performed, using the yeast two-hybrid system. The PP1γ1, PP1γ2 and PP1α 
were used as baits and this methodology was used to screen a human brain cDNA library. 
The binding domain plasmid carries the yeast TRP1 gene and, for example, the PP1γ1 
sequence (the bait) fused to GAL4-BD. The activation domain plasmid carries the yeast 
LEU2 gene and a sequence from the cDNA library (the prey) fused to GAL4-AD. The 
reporter genes used were the MEL-1 gene, which encodes α-Galactosidase, and HIS3 and 
ADE4. The plasmids were transformed into yeast strain which requires tryptophan (Trp), 
leucine (Leu), histidine (His) and adenine (Ade). If the two proteins (the bait and the prey) 
interact the reporter genes will be activated and the yeast will grow on synthetic complex 
medium lacking the amino acids Trp, Leu, His and Ade. The α-Galactosidase activity is 
detected by the formation of blue yeast colonies on medium with the cromogenic substrate 
X-α-Gal (5-bromo-4-chloro-3-indolyl alpha-D-galactopyranoside). 
The brain cDNA library screen, using PP1γ1 as bait identified 300 positives clones, 
four of which were identified as torsinA interacting protein 1 (TOR1AIP1), or lamina 
associated protein 1B (LAP1B). A total of 298 positive clones were obtained in the yeast-
two hybrid (YTH) screen using PP1α as bait, and 14 were identified as LAP1B. Using 
PP1γ2 as bait 298 positive clones were obtained and 2 were identified as LAP1B protein. 
Given that LAP1B was detected with all the PP1 isoforms tested, and since LAP1B is 
known to interact with torsinA, a protein involved in the incurable neurologic disease 
termed early onset torsion dystonia (EOTD), it seemed important to validate the 
PP1/LAP1B interaction. This decision was also supported by the well known involvement 
of PP1 in dopaminergic signalling, thus raising the possibility that PP1 and/or abnormal 
protein phosphorylation may have an important role in EOTD. 
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1.6.Aims of the thesis 
 
Given the various different roles that have been proposed for PP1, concomitant 
with different binding and regulatory subunits, it is important to identify novel PP1 binding 
proteins. Thus a yeast two-hybrid screen of a human brain cDNA library was performed 
using various PP1 isoforms as baits. Among several interesting proteins, LAP1B was 
identified as a novel putative PP1 regulator. The function of LAP1B is poorly understood 
but it is known to interact with torsinA, which is involved in EOTD. Therefore, the main 
goal of this thesis was to validate the interaction of LAP1B with PP1 using a variety of 
methodologies. The specific aims of this thesis were: 
 
- To validate the interaction between LAP1B and different PP1 isoforms by yeast 
co-transformation. 
 
- To determine the likely physiological relevance of the various putative PP1 
binding motifs of LAP1B, using deletion mutants and yeast co-transformation. 
 
- To express LAP1B protein in bacteria. 
 
- To validate the PP1/LAP1B interaction in vitro by blot overlay using purified 
recombinant PP1γ1 protein. 
 
-  To determine the subcellular localization of the PP1/LAP1B complex in 
mammalian cells. 
 
- To validate the physiological PP1/LAP1B interaction in vivo by co-
immunoprecipitation.  
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2. Bioinformatics analysis of LAP1B 
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YTH screenning of a human brain cDNA library using various PP1 isoforms as bait 
identified a novel putative PP1 interactor: torsinA interacting protein 1 (TOR1AIP1) or 
lamina associated protein 1B (LAP1B). Overall, fourteen, four and two positive clones 
encoding LAP1B were identified using PP1α, PP1γ1 and PP1γ2 as baits, respectively 
(Table 1). Sequencing analysis of all LAP1B clones isolated led us to determine that all of 
them represent an alternative splice variant of LAP1B reported in the NCBI database 
(NM_015602), with the only difference being an additional CAG insertion which results in 
the addition of one alanine (Fig. 11). This sequence is identical to that previously reported 
by Kondo et al (2002) (89). For further studies, we choose clone 135 (interaction with 
PP1γ1) which has an insert of 2.0 Kb and encodes the full-length LAP1B (Table 1).  
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Table 1. Summary of LAP1B clones isolated from the yeast-two hybrid (YTH) screens.  
Bait Clone ID Number of clones YTH clone ID Insert (Kb) Start position 
PP1α 
TOR1AIP1 
(NM_015602) 
14 
12 2.0 140 
31 1.75 138 
36 2.25 24 
45 2.15 138 
50 2.75 30 
61 3.85 21 
76 3.5 18 
96 2.2 139 
184 4.3 21 
192 3.75 30 
261 4.0 21 
262 2.1 138 
271 2.2 138 
273 3.75 21 
PP1γ1 
TOR1AIP1 
(NM_015602) 
4 
120 2.4 17 
124 1.5 22 
135 2.0 138 
164 1.6 24 
PP1γ2 
TOR1AIP1 
(NM_015602) 
2 
124 1.8 18 
164 0.3 26 
 
Clone 135 (interaction with PP1γ1) was selected for further study. The start position indicated is relative to 
the GenBank sequence NM_015602. 
 
 
The alternatively spliced isoform of LAP1B (LAP1B’) includes 3 more nucleotides 
(CAG) and results in the inclusion of a single amino acid (alanine) at position 185 of 
LAP1B amino acid sequence (Fig. 11).  
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Figure 11. Analysis of homology between LAP1B sequence in NCBI database (NM_015602) and the 
sequence of the alternatively spliced LAP1B’ isoform isolated in this study. The arrow indicates the site of a 
CAG insertion which results in the insertion of alanine (A) in LAP1B’. 
 
 
The LAP1B gene is localized on chromosome 1 (1q24.2). Alignment of the LAP1B 
cDNA with the corresponding genomic sequence identifies the exon-intron boundaries. 
LAP1B is encoded by 10 exons and the alternative splicing occurs at exon 3 (Fig. 12). 
 
A 
 
 
B 
Intron 
5’ Splice donor site 
Exon 
3’ Splice acceptor site 
Amino acid change 
cctatattagcag cagtgagtgaagatc Val/AlaVal 
 
Figure 12. Shematic representation of the genomic structure of the LAP1B gene, showing the exon-intron 
organization. A- Exons are represented as numbered boxes and introns as gray lines (not to scale). The 
alternative splicing occurs at exon 3 and isoform LAP1B’ includes three more nucleotides (CAG). B- Exon 
and intron boundaries of the isoform LAP1B’. Val- valine; Ala- alanine. 
mRNA 
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Despite the inclusion of the extra CAG in the coding sequence of our clone we will 
refer it here as LAP1B. LAP1B is a type two INM protein with 584 amino acids. LAP1B 
has an N-terminal nucleoplasmic domain, a putative transmembrane domain and a          C-
terminal lumenal domain. In order to obtain an overview of the most important domains 
and motifs present in the LAP1B sequence, a detailed bioinformatic analysis was 
performed. Several interesting putative domains and motifs were identified, including three 
well conserved PP1 binding motifs (BM) (Figs. 13A and 14). BM1, comprising amino 
acids 55-59 (REVRF), and BM2, comprising aa 212-215 (KVNF), are localized in the 
nucleoplasm. BM3 comprises aa 538-541 (KVKF) and is localized in the lumen of the 
perinuclear space. A second generic PP1 binding motif (SILK, aa 306-309) was also 
identified (Figs. 13A and 14). Additionally, the transmembrane domain (aa 339-359) was 
predicted by Goldman and Engelman Steitz hydrophobicity analysis (Fig. 13B).  
The amino acid sequence was obtained using the Expasy Translate tool 
(http://www.expasy.org/tools/dna.html). Various LAP1B putative domains were predicted 
using ELM server (http://elm.eu.org/) and the SILK domain was predicted on ExPASy 
ScanProsite tool (http://www.expasy.ch/tools/scanprosite). The hydrophobicity analysis 
was performed using TopPred (http://mobyle.pasteur.fr/cgi-bin/portal.py?form=toppred). 
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A 
 agaagccatcgccaccaccgg 
 caggagaacctagggtccataaagccatcttcgcgatcgactaaagctacgtcaacaact 
   82 atggcgggcgacgggcggcgggcagaggcggtgcgggaaggatggggtgtgtacgtcacc 
  M  A  G  D  G  R  R  A  E  A  V  R  E  G  W  G  V  Y  V  T  20 
  142 cccagggcccccatccgagagggaaggggccggctcgcccctcaaaatggcggcagcagc 
   P  R  A  P  I  R  E  G  R  G  R  L  A  P  Q  N  G  G  S  S  40 
  202  gatgcgcctgcgtacagaactcctccgtcgcgccagggccggcgggaagtgaggttctcg 
   D  A  P  A  Y  R  T  P  P  S  R  Q  G  R  R  E  V  R  F  S  60 
  262  gacgagccgccagaagtgtacggcgacttcgagcccctggtggccaaagaaaggtccccg 
   D  E  P  P  E  V  Y  G  D  F  E  P  L  V  A  K  E  R  S  P  80  
  322  gtgggaaaacgaacccggctagaagagttccggtccgattctgcgaaagaggaagtgaga 
   V  G  K  R  T  R  L  E  E  F  R  S  D  S  A  K  E  E  V  R  100 
  382  gaaagcgcgtactaccttcggtctaggcagcggaggcagccgcgaccccaggaaaccgag 
   E  S  A  Y  Y  L  R  S  R  Q  R  R  Q  P  R  P  Q  E  T  E  120 
  442  gaaatgaagacgcgaaggactacccgccttcagcagcagcactcagagcagcctccgcta 
  E  M  K  T  R  R  T  T  R  L  Q  Q  Q  H  S  E  Q  P  P  L  140 
  502  cagccgtctcctgttatgaccaggagagggctgcgggactctcattcctctgaagaggat 
  Q  P  S  P  V  M  T  R  R  G  L  R  D  S  H  S  S  E  E  D  160 
  562  gaagcatcttcccaaactgatttaagccaaacgatctcaaagaaaactgtcaggagcata 
   E  A  S  S  Q  T  D  L  S  Q  T  I  S  K  K  T  V  R  S  I  180 
  622  caagaggctccagcagtgagtgaagatcttgtaatcaggttacgtcgaccccctctaaga 
   Q  E  A  P  A  V  S  E  D  L  V  I  R  L  R  R  P  P  L  R  200 
  682  tacccaagatatgaagccaccagtgtccaacagaaggtcaatttctctgaagaaggagaa 
   Y  P  R  Y  E  A  T  S  V  Q  Q  K  V  N  F  S  E  E  G  E  220 
  742  actgaagaagatgatcaagacagctctcacagcagtgtcactactgttaaggccagatcc 
   T  E  E  D  D  Q  D  S  S  H  S  S  V  T  T  V  K  A  R  S  240 
  802  agggattctgatgaatctggagataaaaccaccagatcatctagtcaatatatagaatca 
  R  D  S  D  E  S  G  D  K  T  T  R  S  S  S  Q  Y  I  E  S  260 
  862  ttttggcagtcatcacaaagtcaaaacttcacagctcatgataagcaaccttcagtgcta  
  F  W  Q  S  S  Q  S  Q  N  F  T  A  H  D  K  Q  P  S  V  L  280 
  922  agctcaggatatcaaaaaactccccaggaatgggccccacaaactgcaagaataaggacc 
  S  S  G  Y  Q  K  T  P  Q  E  W  A  P  Q  T  A  R  I  R  T  300 
  982  aggatgcaaaatgacagcattctgaaatcagagcttggaaaccagtcaccatcaacctcc 
  R  M  Q  N  D  S  I  L  K  S  E  L  G  N  Q  S  P  S  T  S  320 
 1042 agccgacaagtgactggacaaccccaaaatgcatcttttgtcaagaggaaccggtggtgg 
  S  R  Q  V  T  G  Q  P  Q  N  A  S  F  V  K  R  N  R  W  W  340 
 1102 ctacttcctctgatagctgctcttgcctctgggagtttttggttctttagtactcctgag 
      L  L  P  L  I  A  A  L  A  S  G  S  F  W  F  F  S  T  P  E  360 
 1162 gtagaaaccactgctgttcaagagttccagaaccagatgaatcaacttaagaataagtac 
      V  E  T  T  A  V  Q  E  F  Q  N  Q  M  N  Q  L  K  N  K  Y  380 
 1222 caaggtcaagatgagaagctgtggaaaaggagccaaacattcctggaaaaacatcttaat 
      Q  G  Q  D  E  K  L  W  K  R  S  Q  T  F  L  E  K  H  L  N  400 
 1282 agctcccatcctcggtctcagcctgctatcttactgctcactgctgcccgagatgctgaa 
      S  S  H  P  R  S  Q  P  A  I  L  L  L  T  A  A  R  D  A  E  420 
 1342 gaagcacttaggtgtctgagtgaacaaattgctgatgcctattcttcttttcgtagtgtc 
      E  A  L  R  C  L  S  E  Q  I  A  D  A  Y  S  S  F  R  S  V  440 
 1402 cgtgccatccggattgatgggacagataaagctactcaagacagtgatactgtcaaacta 
      R  A  I  R  I  D  G  T  D  K  A  T  Q  D  S  D  T  V  K  L  460 
 1462 gaggtagaccaagaactgagcaatggatttaagaatggccagaatgcagctgtggtacac 
      E  V  D  Q  E  L  S  N  G  F  K  N  G  Q  N  A  A  V  V  H  480 
 1522 cgctttgagtcatttcccgcaggctctactttgatcttctacaaatattgtgaccatgaa 
      R  F  E  S  F  P  A  G  S  T  L  I  F  Y  K  Y  C  D  H  E  500 
 1582 aacgcggccttcaaagatgtagccttagtcctgactgtcttattggaggaagagacactt 
      N  A  A  F  K  D  V  A  L  V  L  T  V  L  L  E  E  E  T  L  520 
 1642 ggaacaagtctaggcctaaaggaagttgaagaaaaagtaagagattttcttaaagtcaag 
     G  T  S  L  G  L  K  E  V  E  E  K  V  R  D  F  L  K  V  K  540 
 1702 ttcaccaattctaacacacccaactcctacaatcatatggacccagacaaactgaatggc 
      F  T  N  S  N  T  P  N  S  Y  N  H  M  D  P  D  K  L  N  G  560 
 1762 ctctggagccgtatttctcacttagttctgcctgtgcaacctgaaaatgccctgaaaagg 
      L  W  S  R  I  S  H  L  V  L  P  V  Q  P  E  N  A  L  K  R  580 
 1822 ggcatctgctta 
      G  I  C  L         584 
 1882 taagaagtgagagagaagaaaaatcatgtcccaagttctgagaattgttcacactttcta 
 1942 accagagacagaattcagagctctttttgaaagaactagtttctttttaaagaagttaag 
 2002 tgcttacataaacatggaacatataaatcattcattcaacct 
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B 
 
Figure 13. A- Nucleotide and corresponding amino acid sequence of human LAP1B encoded by clone 135. 
Stop and start codons are coloured blue. The three well conserved PP1 binding motifs (RVxF) are 
highlighted in red (positions 55-59, 212-215 and 538-541 in aa sequence) and a second generic PP1binding 
motif (SILK) is coloured green (position 306-309 in aa sequence). The putative transmembrane domain is 
highlighted in orange (position 339-359 in aa sequence). B- Goldman and Engelman Steitz hydrophobicity 
highlighting the occurrence of a single transmembrane domain. 
 
 
Furthermore, LAP1B possesses several potential phosphorylation sites for casein 
kinase 1 (CK1) and casein kinase 2 (CK2), glycogen synthase kinase 3 (GSK3) and polo-
like kinase (PLK) (Fig. 14). A nuclear receptor box (NRBOX) motif that confers binding 
to nuclear receptor was also predicted. Additionally, LAP1B also contains a motif 
recognized for modification by the small ubiquitin-like modifier-1 (SUMO-1) and a UHM 
ligand motif (ULM) found in splicing factors SF1 and SAP155 (Fig. 14). These LAP1B 
putative domains were predicted using ELM (http://elm.eu.org/). 
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Figure 14. Schematic illustration of LAP1B protein and its putative domains. BM1, PP1 binding motif  1; 
SUMO-1, motif recognized for modification by small ubiquitin-like modifier-1 (SUMO-1); BM2, PP1 
binding motif 2; SILK, a second generic PP1binding motif; ULM, pattern encompassing the ULMs (UHM 
ligand motifs) in SF1 and SAP155; TM, transmembrane domain; PLK, site phosphorylated by the polo-like-
kinase (PLK), NRBOX, nuclear  receptor box motif; BM3, PP1 binding motif 3; INM, inner nuclear 
membrane; ONM, Outer nuclear membrane.   
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3. Validation of the PP1/LAP1B interaction 
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3.1.Validation of the PP1/LAP1B interaction by yeast co-transformation 
 
3.1.1.  Introduction 
 
The yeast two-hybrid system is a method enabling the detection of the interactions 
between proteins and is also used to search for unknown partners (the prey) of a given 
protein (the bait). This method is based on the properties of the yeast GAL4 protein, which 
possesses two separable domains, one responsible for DNA binding and the other for 
transcriptional activation. To identify proteins expressed in human brain that interact with 
different PP1 isoforms, this methodology was used with PP1α, PP1γ1 and PP1γ2 as bait 
(previous work from our laboratory). The cDNAs encoding those PP1 isoforms were 
transferred into the GAL4-BD pAS2-1 expression vector (Appendix II), which carries the 
yeast TRP1 gene. The brain cDNA library was cloned into the pACT2 vector, which 
contains the yeast LEU2 gene (Appendix II), in frame with GAL4-AD. As described 
previously among the positives identified was LAP1B. In order to confirm the interaction 
between LAP1B and all PP1 isoforms a yeast co-transformation assay was performed, 
combining the bait plasmids pAS2-1-PP1α, pAS2-1-PP1γ1, pAS2-1-PP1γ2 or pAS2-1-
PP1γ2end (carrying the specific C-terminus of the protein) with the prey plasmid pACT2-
LAP1B (clone 135 from the PP1γ1 YTH screen, encoding the full-length LAP1B). 
Additionally, in order to determine the PP1 binding motif (BM) of LAP1B responsible for 
the interaction with PP1γ1, several deletion mutants (Fig. 15) were produced and co-
transformed with PP1γ1. These constructs were cloned into the pACT2 vector and fused 
with GAL4-AD. Each construct contained one of the three well conserved PP1 binding 
motifs (BM1, BM2 or BM3) and one construct included both BM1 and BM2 (Fig. 15). All 
constructs were fully verified by DNA sequencing. 
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LAP1B constructs (in pACT2) 
Full-lenght 
 
 
Deletion 
mutants 
 
 
 
 
 
 
 
Figure 15. Schematic illustration of the LAP1B and LAP1B deletion mutants used. The red boxes represent 
the three well conserved putative PP1 binding motifs (BMs) present in the constructs and the yellow boxes 
represent the transmembrane domain.  
 
 
In order to validate the PP1/LAP1B interaction and to determine the PP1 binding 
motif of LAP1B responsible for this interaction, full-length LAP1B or LAP1B deletion 
mutants and PP1 were co-transformed in the AH109 yeast strain. The reporter genes used 
were MEL-1 which encodes α-Galactosidase and HIS3 and ADE4. If the two proteins (the 
bait and the prey) interact, the reporter genes will be activated and the yeast will grow on 
synthetic complex medium lacking the amino acids Trp, Leu, His and Ade. The α-
Galactosidase activity is detected by the formation of blue yeast colonies on medium with 
the chromogenic substrate X-α-Gal (5-bromo-4-chloro-3-indolyl alpha-D-
galactopyranoside). 
 
  
LAP1B  
LAP1B – BM2 
LAP1B – BM1/2 
LAP1B – BM3 
LAP1B – BM1 
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3.1.2. Materials and methods 
 
3.1.2.1. Bacterial transformation 
 
Preparation of E. coli XL1-Blue competent cells 
 
A single colony of E. coli XL1-Blue was incubated in 10 mL of SOB medium 
(Appendix I) at 37ºC overnight. Then, 1 mL of this culture was used to inoculate 50 mL of 
SOB and the culture was incubated at 37ºC with shaking at 180 rpm for 1-2 hr, until 
OD550nm=0.3. The culture was cooled on ice for 15 min and centrifuged at 4000 rpm at 4ºC 
for 5 min. The supernatant was discarded and the pellet resuspended in 15 mL of Solution I 
(Appendix I). After standing on ice for 15 min, the cells were centrifuged at 4000 rpm for 
5 min at 4ºC and 3 mL of Solution II (Appendix I) were added to resuspend the cell pellet. 
The cells were immediately divided in 100 µL aliquots and stored at -80ºC. 
 
E. coli XL1-Blue transformation 
 
Competent cells (50 µL) were thawn on ice and 5 ng of DNA were added to the 
cells and gently swirled. The microtube was incubated on ice for 20 min and heat shocked 
at 42ºC for 70 sec. The microtubes were then incubated on ice for 2 min before adding 450 
μL of SOC medium (Appendix I). The tubes were subsequently incubated at 37ºC for 60 
min with shaking at 190 rpm. The culture was centrifuged at 14000 rpm during 1 min and 
the supernatant was discarded. The cells were then resuspended in the remaining 
supernatant and spread on the appropriate agar medium. The plates were incubated at 37ºC 
for 16 hr until colonies appeared. Control transformations were also performed in parallel. 
These included a negative control transformation without DNA and a positive control 
transformation with 1 ng of a control plasmid, such as pAS2-1. 
 
3.1.2.2. Isolation and purification of plasmid DNA 
 
A single bacterial colony was transferred into 50 mL of LB medium (Appendix I) 
containing ampicillin (100 µg/mL) and incubated overnight at 37ºC with shaking (190 
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rpm). The bacterial culture was poured into a 50 mL tube and centrifuged at 4000 g for 10 
min. The supernatant was discarded and the pellet was ressuspended in 3 mL of Cell 
Resuspension Solution (Appendix I). Next, 3 mL of Cell Lysis Solution (Appendix I) was 
added to the cells, mixed by gently inverting the tube 5 times and left to incubate for 3 min. 
Then, 5 mL of Neutralization Solution (Appendix I) were added and immediately mixed by 
gentle tube inversion; the lysate was allowed to sit for 3 min. After this initial procedure 
DNA Purification by Centrifugation (Promega) was carried out according to the 
manufactures protocol. A blue PureYield
TM
Clearing Column (Promega) was placed in a 50 
mL plastic tube, the lysate was transferred to the column and allowed to incubate for 2 
min. The column assembly to the tube was then centrifuged at 1500 g for 5 min.  A white 
PureYield
TM 
Binding Column (Promega) was assembled in a new 50 mL tube and the 
filtered lysate was transferred to this column and centrifuged at 1500 g for 3 min. The 
column was washed by adding 5 mL of Endotoxin Removal Wash solution (Appendix I) 
and centrifugating at 1500 g for 3 min. After that, 20 mL of Column Wash solution 
(Appendix I) were added and the column centrifuged at 1500 g for 5 min. The flowthrough 
was discarded and an additional 10 min, 1500 g centrifugation was performed. Afterwards, 
the column was placed in a new 50 mL disposable plastic tube and 600 L of Nuclease-
Free Water were added to the column. After 1 min standing, the DNA was eluted by 
centrifugation at 1500 g for 5 min.  
 
3.1.2.3.  Ethanol precipitation 
 
Approximately 1/10 volume of sodium acetate (3M) and 2.5 volumes of 100% 
ethanol were added to the DNA samples. The samples were vortexed and incubated for 20 
min at -20°C. Then the samples were centrifuged for 20 min at 14000 rpm and 4°C. The 
supernatants were discarded and the pellets rinsed with 250 μL of 70% ethanol, and then 
the samples were incubated for 5 minutes at -20°C before new centrifugation for 5 minutes 
at 14000 rpm and 4°C. After discarding the supernatant, the pellet was dried in a Speedvac. 
The pellet was resuspended in 50 μL of water and the DNA concentration and 260/280 nm 
purity ratio was calculated by absorbance measurements. 
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3.1.2.4. Restriction fragment analysis of DNA 
 
Plasmid DNAs were analysed by digestion with two convenient restriction 
endonucleases, namely EcoRI and XhoI (New England Biolabs). For plasmid DNA 
digestion the manufacturer’s instructions were followed. In a microtube the following 
components were added: 500 ng DNA; 1x reaction buffer (Neb 2); 0.1 μg/μl BSA and       
1 U/µg DNA of restriction enzyme. The volume was made up to 20 μl with distilled H20 
and the mixture was incubated at the appropriate temperature (37ºC) for 4 hr before further 
analysis. 
 
3.1.2.5.  Electrophoretic analysis of DNA 
 
The electrophoresis apparatus was prepared and the electrophoresis tank was filled 
with enough 1x TAE (Appendix I) to cover the agarose gel. The appropriate amount of 
agarose was transferred to an Erlenmeyer with 100 mL 1x TAE. The slurry was heated 
until the agarose was dissolved and allowed to cool to 60ºC before adding ethidium 
bromide to a final concentration of 0.5 µg/mL. The agarose solution was poured into the 
mold and the comb was positioned. After the gel became solid the comb was carefully 
removed and the gel mounted in the tank. The DNA samples were mixed with the 6x 
loading buffer (LB) and the mixture was loaded into the wells of the submerged gel using a 
micropipette. Marker DNA (1 Kb ladder) of known size was also loaded onto the gel. The 
lid of the gel tank was closed and the electrical cables were attached so that the DNA 
migrated towards the anode. The gel was run until the bromophenol blue had migrated the 
appropriate distance through the gel. At the end, the gel was examined under UV light and 
photographed or otherwise analysed on a Molecular Imager (Biorad). 
  
3.1.2.6. DNA sequencing 
 
All the DNA samples to be sequenced were purified using the Promega Pure 
Yield
TM 
Plasmid Midiprep System, as described above in section 3.1.2.2. Sequencing 
reactions were performed as follows: 
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Sequencing PCR reaction 
 
The following components were mixed in a 0.2 mL microtube: 
500 ng dsDNA  
4 µL Ready Reaction Mix* 
10 pmol primer  
H2O to a final volume of 20 µL 
 
* Ready Reaction Mix is composed of dye terminators, deoxynucleoside 
triphosphates, AmpliTaq DNA polymerase, FS, rTth pyrophosphatase, magnesium 
chloride and buffer (Applied Biosystems). 
 
This reaction mixture was vortexed and span down for a few seconds. The PCR 
was then performed using the following conditions: 
96ºC 1 min 
96ºC 30 sec 
42ºC 15 sec     25 cycles 
60ºC 4 min 
 
The samples were purified after PCR by ethanol precipitation, as described above. 
Finally the DNA was sent to the sequencing facility for analysis using an automated DNA 
sequencer (ABIPRISM 310, Applied Biosystems). 
 
3.1.2.7. Verifying protein interactions by yeast co-transformation  
 
In order to verify protein interactions, a small-scale LiAc yeast co-transformation 
procedure was performed, combining one of the bait plasmids (pAS2-1-PP1α, pAS2-1-
PP1γ1, pAS2-1-PP1γ2 or pAS2-1-PP1γ2end) with one of the specific target proteins [full-
length LAP1B or its deletions mutants (BM1, BM2, BM1/2 and BM3)]. In parallel, co-
transformation of the vectors pAS2-1 and pACT2 and transformation with LAP1B were 
performed as a negative control. The association of murine p53 (encoded by plasmid 
pVA3) and SV40 large T antigen (plasmid pTD1) was used as a positive control.  
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Preparation of competent yeast cells 
 
One yeast colony was inoculated into 1 mL of YPD medium (Appendix I) in a 1.5 
mL microtube and vortexed vigorously to disperse cell clumps. The culture was transferred 
into a 250 mL flask containing 50 mL of YPD and incubated at 30ºC with shaking at 230 
rpm overnight, until it reached stationary phase with OD600nm > 1.5. Enough of this culture 
(30 mL) was transferred into 300 mL YPD in a 2 L flask to yield an OD600nm= 0.2-0.3. The 
culture was incubated at 30ºC with shaking at 230 rpm, until OD600nm = 0.4-0.6, and then 
centrifuged at 2200 rpm for 5 min, and the supernatant was discarded and the cells 
resuspended in 25 mL H2O. The cells were recentrifuged and the pellet was resuspended in 
1.5 mL of freshly prepared, sterile 1x TE/LiAc (Appendix I).  
 
Yeast transformation by the lithium acetate (LiAc)-mediated method 
 
In a microtube 0.1 μg of plasmid DNA were added to 0.1 mg of salmon testis 
carrier DNA. Then, 100 µL of freshly prepared competent cells were added to the 
microtube, followed by 600 µL of sterile PEG/LiAc (40% PEG 4000/ 1X TE/ 1X LiAc). 
The mixture was incubated at 30ºC for 30 min with shaking (200 rpm). After adding 70 µL 
of DMSO the solution was mixed gently and then heat-shocked for 15 min in a 42ºC water 
bath. The cells were chilled on ice for 1-2 min and pelleted by centrifugation for 5 sec at 
14000 rpm and resuspended in 0.5 mL of 1x TE buffer. The cells (100 µL) were then 
plated in SD/-Trp-Leu plates and in SD/-Leu plate for LAP1B (negative control) and 
incubated at 30ºC for 2-4 days, until colonies appeared. To confirm protein-protein 
interactions a colony was picked and transferred to a SD/TDO (-Trp-Leu-His) plate and a 
SD/QDO (-Trp-Leu-His-Ade) plate, and latter to a SD/TDO/X-α-Gal plate and a 
SD/QDO/X-α-Gal plate. 
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3.1.3.  Results  
 
3.1.3.1. Electrophoretic analysis of the constructs 
 
All constructs (full-length LAP1B and LAP1B deletion mutants) used for yeast co-
transformation analysis, were first verified by restriction analysis to confirm the correct 
insertion into the pACT2 vector. The constructs were transformed into E. coli XL1-Blue 
and the DNA isolated was analysed by restriction digestion with the endonucleases EcoRI 
and XhoI. The restriction fragments were then separated by 1.3% agarose gel 
electrophoresis to confirm the correct size of the insert (Fig. 16). 
 
 
Figure 16. Restriction analysis of LAP1B constructs. Lane M, 1 Kb Plus DNA ladder marker; Lane 1, 
pACT2 vector (8.1 Kb); Lane 2, pACT2 + full-length LAP1B insert (8.1 + 2.0 Kb); Lane 3, pACT2 +  BM1 
insert (8.1 + 0.6 Kb); Lane 4, pACT2 + BM2 insert (8.1 + 1.3 Kb); Lane 5, pACT2 + BM1/2 insert (8.1 + 1.5 
Kb); Lane 6, pACT2 + BM3 insert (8.1 + 1.0 Kb). 
 
 
3.1.3.2. DNA sequence analysis 
 
All LAP1B constructs were further analysed by DNA sequencing to confirm the 
absence of mutations and to validate the correct insertion into the pACT2 vector and 
reading frame of the fusion proteins. All constructs were sequenced with the appropriate 
primers (Appendix III). Figure 17 shows an example of a sequencing result obtained using 
the Chromas program.  
 
M          1           2         3     4           5          6    
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Figure 17. Partial nucleotide sequence obtained for full-length LAP1B, visualized using the Chromas 
program. 
 
 
The nucleotide sequence of each construct was converted to FASTA format and 
then copied to the BLAST window (www.ncbi.nlm.nih.gov/BLAST/) to be compared with 
the GenBank Database of human nucleotide sequences. The sequence alignment with the 
LAP1B sequence present in the GenBank Database was obtained and one example is 
presented in Figure 18. 
 
 
Figure 18. Blast results for alignment of LAP1B construct sequence obtained with the LAP1B sequence 
present in the GenBank database. Ambiguities present in the query sequence were further validated by visual 
verification of the sequencing results. 
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3.1.3.3. Validation of the PP1/LAP1B interaction by yeast co-transformation  
 
In order to confirm the interaction between LAP1B with various PP1 isoforms, a 
yeast co-transformation assay was performed. Interaction of LAP1B with the specific C-
terminus of PP1γ2, named PP1γ2end, was also tested. The mapping of the LAP1B domain 
responsible for the interaction with PP1γ1 was performed using LAP1B deletion mutants. 
Constructs corresponding to full-length LAP1B and LAP1B deletions (the prey in the 
pACT2 vector) and the various PP1 isoforms (the bait in the pAS2-1 vector) were co-
transformed in yeast strain AH109 and tested in SD/TDO, SD/QDO, SD/TDO/X-α-gal and 
SD/QDO/X-α-gal medium. If interaction occurs the colonies will grow and in the X-α-gal 
plates they will appear blue. The results obtained showed that LAP1B interacts with the 
three PP1 isoforms tested (PP1α, PP1γ1 and PP1γ2) but does not interact with the C-
terminus of PP1γ2 (PP1γ2 end) (Fig 19A). Moreover, the assay was positive for 
PP1γ1/LAP1B interaction through BM1 (Fig. 19B), but was negative for interaction 
through BM2 and BM3 (Fig. 19B). The construct with both BM1 and BM2 (BM1/2) also 
yielded a positive result with PP1γ1 (Fig. 19B). 
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LAP1B 
 
PP1α 
PP1γ1 
 PP1γ2 
PP1γ2 end 
 
 PP1γ1 
LAP1B - BM1 
 
 
LAP1B - BM2 
LAP1B - BM1/2 
LAP1B - BM3 
 
Control (+)           Control (-) 
 
 
 
Figura 19. Yeast co-transformation assay in SD/QDO/X-α-gal medium. A- Positive interactions were 
observed between LAP1B and PP1α, PP1γ1 and PP1γ2. B- PP1γ1 interacted with LAP1B-BM1 and BM1/2 
but not with LAP1B-BM2 and BM3. C- Positive (+) and negative (-) controls were also included as 
described in the methods. In the schematic representations, the red boxes represent the BMs present in the 
constructs and the yellow boxes represent the transmembrane domains of LAP1B.  
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3.1.4.  Discussion 
 
From the yeast-two hybrid screens of a human brain cDNA library using various 
PP1 isoforms as bait, a novel PP1 interactor was identified: LAP1B or TOR1AIP1. 
Confirmation of the interaction in yeast was performed by co-transformation of strain 
AH109 and assaying for X-α-Gal activity resulting from expression of the MEL-1 reporter 
gene. Interaction of LAP1B with PP1 α, γ1 and γ2 isoforms was tested and the results were 
positive for all isoforms. However, LAP1B does not interact with the specific C-terminus 
of PP1γ2, demonstrating that this region is not responsible for the interaction. LAP1B has 
three putative PP1 binding motifs: BM1 and BM2 located in the nucleoplasm, and BM3 in 
the lumenal space. Using LAP1B deletion mutants, the mapping of the LAP1B domain 
responsible for the interaction with PP1γ1 was performed. Our results indicated that 
LAP1B interacts with PP1γ1 through BM1. A positive result was also obtained with 
LAP1B-BM1/2 construct. However, negative results were observed for LAP1B-BM2 and 
LAP1B-BM3. These results thus indicate that it is the BM1 of LAP1B which mediates the 
primary interaction between PP1 and LAP1B. Since BM1 is located in the nucleoplasmic 
domain of LAP1B, these results are consistent with the high abundance of PP1 in the 
nucleus. 
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3.2. Validation of the PP1/LAP1B interaction using an in vitro blot overlay assay 
 
3.2.1. Introduction 
 
The pET system is arguably the most powerful system developed for cloning and 
expression of recombinant proteins in Escherichia coli. Target genes are cloned in pET 
plasmids under the control of bacteriophage T7 transcription and (optionally) translational 
signals and expression is induced by providing a source of T7 RNA polymerase. Addition 
of isopropyl-β-D-thiogalactopyranoside (IPTG) to a growing culture induces T7 RNA 
polymerase production, which will transcribe the target DNA of the plasmid. Various 
constructs expressing either full-lenght LAP1B or different fragments comprising the 
nucleoplasmic or lumenal domains of LAP1B (with or without the transmembrane domain) 
were generated in pET-28c (Fig. 20). 
 
LAP1B constructs (in pET-28c) 
Full-lenght 
 
 
Deletion 
mutants 
 
 
 
 
 
 
Figure 20. Schematic representation of full-length LAP1B and LAP1B deletion mutants expressed in E. coli. 
The red boxes represent the PP1 binding motifs (BMs) present in the constructs. TM, transmembrane 
domain, +TM, with transmembrane domain; -TM, without transmembrane domain.  
 
 
pET-28 is a translation vector with an N-terminal 6xHis-tag and possesses the 
Kanamycin resistance gene (Appendix II). The His-tag allows easy detection of the fusion 
LAP1B 
LAP1B - BM1/2-TM 
LAP1B - BM3+TM  
LAP1B - BM3-TM 
LAP1B - BM1/2+TM 
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protein by Western blotting and is very useful for protein purification, especially for those 
proteins initially expressed as inclusion bodies. The E. coli Rosetta strains used in this 
study are designed to enhance expression of eukaryotic proteins that contain codons rarely 
used in E. coli and that would otherwise hamper translation.  
A time course, after IPTG induction, was performed in order to determine the 
optimal time of expression of recombinant full-length LAP1B and LAP1B deletion 
mutants. The soluble and insoluble fractions were recovered and tested. To confirm the 
interaction of LAP1B with PP1γ1 and to determine the LAP1B domain responsible for the 
interaction with PP1γ1, an in vitro blot overlay assay was performed using purified PP1γ1 
protein (readily available in our laboratory).  
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3.2.2. Materials and methods 
 
Isolation and purification of recombinant plasmids was performed using the 
Promega Pure Yield Plasmid Midiprep System. The plasmid DNA was further analysed by 
digestion with the restriction enzymes EcoRI and XhoI. The restriction fragments were 
then separated by agarose gel electrophoresis and the plasmid DNA was sequenced to 
confirm the nucleotide sequence, as previously described in sections 3.1.2.1 - 3.1.2.6.  
 
3.2.2.1. Expression of recombinant proteins in E. coli  
 
Transformation of the Rosetta (DE3) E. coli strain with recombinant plasmid DNA 
was performed as described for E. coli XL1 Blue cells. A single bacterial colony was 
transferred into 5 mL of LB medium containing Kanamycin (30 μg/mL) and incubated 
overnight at 37ºC with shaking (190 rpm). After incubation 500 μL of the overnight culture 
was added to 50 ml of LB with Kanamycin, until the OD600 was around 0.5-0.6. Then 10 
ml of the culture were transferred into a new tube (non-induced, control). Induction was 
started by adding 1 mM IPTG to the remaining culture. The samples were placed back in 
the incubator (37˚C, 190 rpm) and 10 mL of the culture were harvested after 1, 3 and 5 hr, 
and all samples including the control at 5 hr were centrifuged at 4000 rpm for 10 min. The 
pellets were stored at -20°C. The cells were thawed and resuspended in 500 μL of 1x PBS 
and transferred to microtubes. Then the cells were lysed by sonication, with pulses of 10 
sec, 3 times. After sonication the cells were centrifuged for 30 min at 13200 rpm at 4˚C. 
The supernatant was transferred to a new microtube (soluble fraction). The pellet was 
resuspended in 500 μL of 1x PBS and centrifuged for 10 min at 13200 rpm at 4°C. The 
supernatant was discarded and the pellets resuspended in 500 μL of boiling 1% SDS 
(insoluble fraction). The samples were loaded onto two identical gels, one was stained with 
Coomassie blue and the other was used for immunoblotting analysis. The negative controls 
used include the pET-28c vector without an insert or with an insert but non-induced. As a 
positive control the pET28c-Nek2A was used, given that Nek2A is a well known protein 
that strongly interacts with PP1. 
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3.2.2.2. BCA protein assay 
 
Measurements of total protein concentration were carried out using Pierce’s BCA 
protein assay kit, following the manufacturer’s instructions. This method combines the 
reduction of Cu
2+
 to Cu
+
 by proteins in an alkaline medium (the biuret reaction), with a 
sensitive colorimetric detection of the Cu
+ 
cation using a reagent containing bicinchoninic 
acid (BCA). The purple-coloured reaction product of this assay is formed by the chelation 
of two molecules of BCA with one Cu
+
 ion. This water-soluble complex exhibits a strong 
absorbance at 562 nm that is linear with increasing protein concentration over a working 
range of 20 g/mL to 2000 g/mL. At least duplicates of all samples were assayed by this 
method, as well as the appropriate protein standards as described below (Table 2). 
 
Table 2. Standard curve used in the BCA protein assay. 
Standard BSA (μL) 10% SDS (μL) H20 (μL) Protein mass (μg) W.R. (mL) 
P0 0 5 45 0 1 
P1 1 5 44 2 1 
P2 2 5 43 4 1 
P3 5 5 40 10 1 
P4 10 5 35 20 1 
P5 20 5 25 40 1 
P6 40 5 5 80 1 
 
W.R. - Working reagent. 
 
The Working Reagent was prepared by mixing BCA reagent A with BCA reagent 
B in the proportion of 50:1. Then, 1 mL of WR was added to each microtube (standards 
and samples) and the microtubes were incubated at 37ºC for 30 min. Once the tubes cooled 
to room temperature the absorbance was measured at 562 nm. A standard curve was 
obtained by plotting BSA standard absorbance vs BSA concentration, and it was then used 
to determine the total protein concentration of each sample. 
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3.2.2.3. SDS-PAGE  
 
Samples were subjected to SDS polyacrylamide gel electrophoresis (SDS-PAGE). 
In SDS-PAGE the migration of the proteins is determined by their molecular weight. For 
the time course analysis and to visualize the full-length LAP1B protein, with a molecular 
weight around 65 kDa, a 7.5% polyacrylamide gel was used (Table 3). To visualize 
LAP1B deletion mutants BM1/2+TM and BM1/2-TM, with a calculated molecular weight 
of 41 and 38 kDa, respectively, a 10% polyacrylamide gel was used and for BM3+TM and 
BM3-TM, with 28 and 24 kDa, respectively, a 12% polyacrylamide gel was used (Table 
3). For the blot overlay analysis a 10% polyacrylamide gel was used. 
 
Table 3. Composition of the running and stacking gels for SDS-PAGE. 
Components 
Running gel 
(7.5%) 
Running gel 
(10%) 
Running gel 
(12%) 
Stacking gel 
(3.5%) 
Water 4.9 mL 4.2 mL 3.45 mL 3.3 mL 
30%Acryl/8%Bisacryl. 2.5 mL 3.3 mL 4 mL 0.6 mL 
4x LGB 2.5 mL 2.5 mL 2.5 mL --- 
5x UGB --- --- --- 1.0 mL 
SDS 10% --- --- --- 50 μL 
10% APS 50 μL 50 μL 50 μL 50 μL 
TEMED 5 μL 5 μL 5 μL 5 μL 
 
APS, Ammonium Persulfate; LGB, Lower Gel Buffer; SDS, Sodium Dodecyl Sulphate; UGB, Uper gel 
Buffer.  
 
The running and the stacking gels were prepared as indicated in Table 3. The 
samples were prepared by the addition of ¼ volume of loading gel (LB) buffer and run at 
100 V for approximately 2 hours. 
 
3.2.2.4. Coomassie blue staining 
 
After running, gels were transferred into Coomassie blue staining solution and left 
for 30 min. After staining, gels were washed with water and destained using destain buffer 
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for 1 hr. After the first hour of destaining, fresh destaining buffer was added and the gel 
was destained overnight.  
 
3.2.2.5. Immunoblotting 
 
In our experimental system, after electrophoresis, proteins were transferred to 
nitrocellulose membranes for 2 hours at 200 mA and then visualised with specific 
antibodies.  
 
Immunodetection by enhanced chemiluminescence (ECL)  
 
ECL
TM
 is a light emitting non-radioactive method for the detection of immobilized 
antigens, conjugated directly or indirectly with horseradish peroxidase-labelled antibodies. 
In order to visualize the proteins the blots were probed with an anti-His primary antibody, 
which recognizes the His-tag of the fusion protein. Briefly, the membranes were soaked in 
1x TBS (5 min). Non-specific binding sites were blocked by incubating the membrane in 
5% low fat milk in 1x TBST (3 hr). The membrane was further incubated with the primary 
antibody (1:1000 dilution) diluted in 3% low fat milk in 1x TBST (2 hr with shaking). 
After three washes of 10 min each in 1x TBST the membrane was incubated with an anti-
mouse horseradish peroxidase conjugated secondary antibody (1:5000 dilution) in 3% low 
fat milk in 1x TBST (2 hr with shaking). The membrane was then washed 3 times with 1x 
TBST for 10 min. Subsequently, the membrane was incubated for 1 min with the ECL 
detection solution (a mixture of equal volumes of solution 1 and solution 2 from the ECL 
kit (Amersham)). After exposure to X-ray film (Kodak), immunoblots were scanned and 
quantited using Quantity One densitometry software (Bio-Rad). 
 
3.2.2.6. Blot overlay assay 
 
The nitrocellulose membranes were soaked in 1x TBS for 5 min. Non-specific 
binding sites were blocked by immersing the membrane in 3% BSA in 1x TBST for 3 hr. 
Then membranes were overlaid with purified PP1γ1 protein (1 μg/mL, purified in our 
laboratory) in 3% BSA in 1x TBST for 2 hr. After washing three times with 1x TBST, to 
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remove excess protein, the bound PP1γ1 was detected by incubating the membrane with 
polyclonal anti-PP1γ antibody (CBC3C; 1:5000 dilution in 1x TBST/3% non-fat milk) for 
2 hr. After three washes of 10 min each in 1x TBST the membrane was incubated with a 
solution of an anti-rabbit secondary antibody (1:5000 dilution) in 3% low fat milk in 1x 
TBST for 2 hr with shaking. The membrane was then washed 3 times with 1x TBST for 10 
min and further developed using the ECL kit. 
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3.2.3. Results 
 
3.2.3.1. Restriction analysis 
 
All constructs (full-length LAP1B and LAP1B deletion mutants) were first 
analysed by restriction digestion with the endonucleases EcoRI and XhoI, to confirm the 
correct insertion into the pET-28c vector (Appendix II). The restriction fragments were 
separated by 1.4% agarose gel electrophoresis and their size was confirmed (Fig. 21). 
 
 
Figure 21. Restriction analysis of LAP1B recombinant plasmids. Lane M, 1 Kb Plus DNA ladder marker; 
Lane 1, pET-28c + full-length LAP1B insert (5.4 + 1.75 Kb); Lane 2, pET-28c + BM1/2+TM (5.4 + 1.11 
Kb); Lane 3, pET-28c + BM1/2-TM (5.4 + 1.02 Kb); Lane 4, pET-28c + BM3+TM (5.4 + 0.76 Kb); Lane 5, 
pET-28c + BM3-TM (5.4 + 0.66 Kb). 
 
The size of the fragments observed was in agreement with the expected size. 
 
3.2.3.2. DNA sequencing analysis 
 
All constructs (full-length LAP1B and deletion mutants) cloned into the pET-28c 
vector were sequenced with the appropriate primers (Appendix III) as previously described 
(section 3.1.3.2). The sequence was verified and the insert orientation and the correct 
reading frame were confirmed. 
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3.2.3.3. Expression of recombinant LAP1B protein in bacteria 
 
The cDNAs encoding full-length LAP1B protein and its deletion mutants 
(BM1/2+TM, BM1/2-TM, BM3+TM, BM3-TM) were inserted into pET-28c vector 
(Appendix II) and transformed in Rosetta (DE3) E. coli strain. The pET-28c vector inserts 
an N-terminal 6xHis-tag into the recombinant proteins which allows the detection of the 
fusion proteins using an anti-His antibody. Expression of the recombinant proteins was 
induced by adding 1 mM IPTG to the growing cultures at 37°C. The optimal time course 
of expression was determined for recombinant LAP1B protein and its deletions mutants by 
taking aliquots at 1, 3, and 5 hours after induction and then analysing the soluble and 
insoluble fractions. Non-induced samples were used as negative controls. The samples 
were analysed by SDS-PAGE, and one gel was stained with Coomassie blue (data not 
shown) and another gel analysed by immunoblotting using the anti-His antibody.  
Recombinant full-length LAP1B protein was mainly found in the insoluble fraction 
(Fig. 22). The observed higher molecular mass protein (approximately 75 kDa) represents 
the full-length fusion protein that seems to achieve maximal expression levels 1 hr after 
induction. However, a smaller band, of approximately 50 kDa (Fig. 22), was also detected 
and may result from proteolytic cleavage of the higher molecular mass protein. Smaller 
proteolytic fragments were also detected in the soluble fraction.  
 
 
Figure 22. Immunoblot analysis of full-length LAP1B fused with 6xHis-tag in bacterial extracts using an 
anti-His antibody. Bacterial cultures were collected 1, 3 and 5 hours (indicated on top) after IPTG (1mM) 
induction at 37°C. Insoluble and soluble fractions were collected. C, non-induced control.  
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Recombinant BM1/2+TM and BM1/2-TM proteins were found both in the 
insoluble and soluble fractions (Fig. 23A and B). However, the recombinant protein levels 
were higher in the insoluble fraction. The BM1/2+TM protein exhibited maximal 
expression levels at 3 hr after IPTG induction (Fig. 23A), while for BM1/2-TM maximal 
expression was seen 5 hr after induction (Fig. 23B). Lower molecular weight bands that 
propably represent proteolytic fragments were also detected. Recombinant BM3+TM 
protein was detected almost exclusively in the insoluble fraction and maximal expression 
occurs 1 hr after induction (Fig. 23C). Recombinant BM3-TM protein was mainly found in 
the insoluble fraction and highest expression levels were observed 5 hr after induction (Fig. 
23D). Nonetheless, at 3 and 5 hr after induction BM3-TM was also detected in the soluble 
form (Fig. 23D). 
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Figure 23. Immunoblot analysis of LAP1B deletion mutants fused with 6xHis-tag in bacterial extracts using 
an anti-His antibody. Immunoblot detection of BM1/2+TM expression (A); BM1/2-TM expression (B); 
BM3+TM expression (C); and BM3-TM expression (D). Bacterial cultures were collected 1, 3 and 5 hours 
(indicated on top) after IPTG (1 mM) induction at 37°C. Insoluble and soluble fractions were collected. C, 
non-induced control. 
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3.2.3.4. Blot overlay assay 
 
In order to confirm the interaction of LAP1B with PP1γ1, a blot overlay assay was 
used. For this purpose, bacterial extracts from pET-28c-LAP1B transformed Rosetta cells 
were loaded on a 10% SDS-PAGE gel and transferred to a nitrocellulose membrane. As 
negative controls the bacterial extracts of pET-28c and non-induced pET-28c-LAP1B were 
used. As positive control, purified Nek2A protein was used. The membrane was first 
incubated with PP1γ1 protein (purified in our laboratory) and then incubated with the anti-
PP1γ antibody, and finally developed by ECL. Immunoblot of increasing amounts of 
LAP1B protein were also detected using an anti-His antibody (Fig. 24A) in parallel with 
the overlay assay (Fig. 24B). For these assays the insoluble fraction of bacterial extract 
collected 3 hr after induction was used. Since most of the recombinant proteins were found 
in the insoluble fraction, at this time point a reasonable level of expression was observed. 
As expected, increasing amounts of recombinant LAP1B were detected concomitant with 
increasing binding of PP1γ1 (Figure 24B), demonstrating its interaction with LAP1B.  
 
 
 
Figure 24. A- Immunoblot analysis of expressed LAP1B using an anti-His antibody. B- Blot overlay of 
LAP1B with PP1γ1 protein. The amount of LAP1B bacterial extract (μL) loaded on each well is indicated. 
NI, non-induced control; pET, pET-28c vector without an insert (negative control); Nek, Nek2A (positive 
control). The insoluble fraction of expressed recombinant LAP1B was collected 3 hours after IPTG (1 mM) 
induction at 37°C. 
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In order to evaluate which domain in LAP1B is responsible for the interaction with 
PP1γ1, a blot overlay assay of LAP1B deletion mutants with PP1γ1 was performed. 
Immunoblot analysis of the same LAP1B deletion mutants using an anti-His antibody was 
also performed (Fig. 25A). For these assays equal amounts of protein from the insoluble 
fraction of bacterial extracts collected 3 hr after induction were separated by SDS-PAGE. 
The results showed that PP1γ1 binds to full-length LAP1B (Fig. 25B) and to BM1/2 with 
or without the presence of the transmembrane domain (Fig. 25B). However, PP1γ1 does 
not interact with the BM3+TM or BM3-TM (Fig. 25B). These results are in agreement 
with the co-transformation results previously described.  
 
 
 
Figure 25. A- Immunoblot analysis of LAP1B (1) and LAP1B deletion mutants (2-5) using an anti-His 
antibody. B- Blot overlay assay of LAP1B (1) and LAP1B deletion mutants (2-5) with PP1γ1. NI, non-
induced control; pET, pET-28c vector without an insert (negative control); Nek, Nek2A (positive control); 1, 
LAP1B; 2, LAP1B – BM1/2+TM; 3, LAP1B – BM1/2-TM; 4, LAP1B – BM3+TM; 5, LAP1B – BM3-TM. 
The insoluble fractions were collected 3 hours after IPTG (1 mM) induction at 37°C and equal amounts of 
protein were separated by SDS-PAGE and transferred to nitrocellulose. 
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3.2.4. Discussion 
 
LAP1B expression was induced in bacteria [Rosetta (DE3) E. coli strain] and 
aliquots were taken at 1, 3 and 5 hr after induction of recombinant protein expression. A 
temperature of 37°C for bacterial growth and a concentration of 1 mM IPTG for induction 
allowed the abundant production of recombinant full-length LAP1B and LAP1B deletion 
proteins. However, most of the recombinant protein expressed was found in the insoluble 
fraction, which may be the result of protein accumulation in inclusion bodies. Since 
LAP1B is an integral membrane protein, that may explain why LAP1B was mainly found 
in an insoluble form. Further, a smaller protein, which may result from proteolytic 
cleavage of the full-length LAP1B protein, was found both in the insoluble and soluble 
fractions. This can be explained by the fact that small proteins are more easily soluble in 
bacteria. Therefore, the LAP1B deletion mutants BM1/2+TM and BM1/2-TM, which 
possess only the nucleoplasmic portion of LAP1B, and the transmembrane domain for 
BM1/2+TM, were found both in the insoluble and soluble fractions. BM3+TM, comprising 
the lumenal and the transmembrane domains, was mostly expressed in the insoluble form. 
However, BM3-TM, lacking the transmembrane domain, had some expression in the 
soluble fraction. In order to optimaize soluble protein expression new conditions of 
expression need to be tested, such as lower temperature for growth and varying the IPTG 
concentration and time of induction.  
PP1 interaction with LAP1B in vitro was demonstrated by blot overlay assay using 
PP1γ1 purified protein. The results obtained confirmed that the interaction of the LAP1B 
with PP1γ1 must be direct (without the need for a bridging protein). The LAP1B domain 
responsible for the interaction with PP1γ1 was assessed by using a blot overlay assay of 
LAP1B deletion proteins with purified PP1γ1 protein. As expected, PP1γ1 binds 
BM1/2+TM and BM1/2-TM which comprise the nucleoplasmic portion of LAP1B. These 
results are in agreement with yeast-co-transformation results demonstrating that PP1γ1 
interacts with LAP1B through BM1 in the nucleoplasm. 
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3.3. Validation of the PP1/LAP1B interaction by co-immunoprecipitation 
 
3.3.1. Introduction 
 
Several procedures may be used to validate a novel putative protein-protein 
interaction. Co-immunoprecipitation is most commonly used to prove that two proteins of 
interest are associated in vivo, but it can also be used to identify novel interacting partners 
of a target protein. Co-immunoprecipitation is based on the formation of antigen-antibody 
complex. Briefly, the target protein is specifically immunoprecipitated from cellular 
extracts using specific antibodies and the immunoprecipitates are then separated by SDS-
PAGE. Co-immunoprecipated proteins are detected by immunoblotting with an antibody 
directed against the protein being evaluated.  
The cDNA encoding LAP1B was transferred into a mammalian expression vector 
with an N-terminal Myc-tag (pCMV-Myc, Appendix II). With the purpose of confirming 
in vivo the interaction of LAP1B with PP1, COS-7 cells were transfected with Myc-
LAP1B and analysed using specific anti-PP1γ, anti-PP1α and anti-Myc antibodies. The 
COS-7 cell line is a mammalian cell line derived from kidney cells of the African green 
monkey and is used for transfection experiments because it yields different expression of 
recombinant proteins. Transfection of COS-7 cells with Myc-LAP1B was performed using 
Lipofectamine 2000 (Invitrogen). Lipofectamine 2000 is a cationic liposome formulation 
that functions by complexing with nucleic acid molecules, allowing them to overcome the 
electrostatic repulsion of the cell membrane and to be taken up by the cell (99).  
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3.3.2. Materials and methods 
 
The Myc-LAP1B construct was amplified and recovered from E. coli XL1-Blue. 
Isolation and purification of plasmid DNA was performed using the Promega Pure Yield 
Plasmid Midiprep System. The Myc-LAP1B construct was further analysed by restriction 
digestion with the endonucleases EcoRI and XhoI and the restriction fragments were 
separated by agarose gel electrophoresis. The Myc-LAP1B construct was fully sequenced 
to confirm the correct insertion of the LAP1B cDNA. These procedures were previously 
described in sections 3.1.2.1 - 3.1.2.6.  
 
3.3.2.1. Cell culture 
 
COS-7 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 mg/mL 
streptomycin and 3.7 g/L NaHCO3 (Complete DMEM). Cultures were maintained at 37ºC 
and 5% CO2. Cells were subcultured whenever approximately 90-95% confluency was 
reached. 
 
3.3.2.2. Transfection with Lipofectamine 
 
COS-7 cells were grown in complete DMEM until 90% confluency was reached 
and on the transfection day the culture medium was replaced with serum and 
antibiotic/antimycotic-free medium. 8 μg of DNA on each plate was diluted in DMEM 
(serum- and antibiotic/antimycotic-free). The Lipofectamine 2000 reagent was diluted in 
the same medium, and the tubes were left for 5 min. The DNA solution was added to the 
Lipofectamine solution drop by drop, and the solution was mixed by gentle bubbling with 
the pipette. In order to form the DNA-lipid complexes, the tube was allowed to rest for 25-
30 min at room temperature. Then, the solution was directly added into the cell medium, 
drop by drop and with gentle rocking of the plate. The cells were then incubated at 37º 
C/5% CO2 for 18 h. After that period cells were collected and further analysed. 
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3.3.2.3. Co-immunoprecipitation procedure 
 
After transfection, COS-7 cells were washed in 1x PBS and collected with 1.2 mL 
of lysis buffer (50 mM Tris-HCl pH 8, 120 mM NaCl, 4% CHAPS) containing a protease 
inhibitor cocktail. The samples were sonicated for 5 seconds three times, intercalating the 
samples in order not to over-heat them. After BCA protein quantification described before 
(in section 3.2.2.2) mass normalized lysates were precleared with 25 L Protein A-
Sepharose beads (Pharmacia), for anti-PP1γ antibody and anti-PP1α antibody, or Protein 
G-Sepahrose beads (Pharmacia), for anti-Myc antibody, for 1 hr at 4ºC with agitation. 
After centrifuging for 5 min at 10000 g at 4ºC, the supernatant was transferred to a new 
microtube and 50 L of Sepharose A plus the primary antibody [polyclonal anti-PP1γ 
(CBC3C) at 1:5000 dilution or polyclonal anti-PP1α (CBC2C) at 1:2500 dilution] or 50 L 
of Sepharose G plus the primary antibody (monoclonal anti-Myc at 1:5000 dilution) was 
added and incubated overnight with shaking at 4º C. The mixture was then centrifuged for 
3 min at 4ºC at 10000 g and the pellet washed four times with 500 L of washing solution 
for 15 min with agitation at 4ºC. After the last wash, the tubes were centrifuged for 10 min 
at 10000 g and 4ºC, and the supernatant was fully discarded. The beads were then 
resuspended in 80 L of Loading Buffer/1% SDS and boiled for 10 min.  
Lysates of the same transfected cells were also collected and the appropriate 
volume of 10% SDS was added in order to obtain a final concentration of 1% SDS. 
Afterwards, they were boiled for 10 min and frozen. 
Immunoprecipitates and lysates were separated by 10% SDS-PAGE and transferred 
to a nitrocellulose membrane that was then incubated with an anti-Myc antibody (1:5000 
dilution) or an anti-PP1γ antibody (CBC3C, 1:5000 dilution) and developed using ECL, as 
previously described.  
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3.3.3. Results 
 
3.3.3.1. Restriction analysis 
 
The Myc-LAP1B construct was analysed by restriction digestion with the 
endonucleases EcoRI and XhoI to confirm the correct insertion into the pCMV-Myc vector 
(Appendix II). The restriction fragments were separated by 1% agarose gel electrophoresis 
and their size was confirmed (Fig. 26). 
 
Figure 26. Analysis of the Myc-LAP1B construct by restriction analysis with EcoRI and XhoI. Lane M, 1 Kb 
Plus DNA ladder marker; Lane 1, pCMV-Myc + full-length LAP1B insert (3.8 + 1.75 Kb).  
 
The fragments observed corresponded to the expected results. 
 
3.3.3.2. DNA sequence analysis 
 
The Myc-LAP1B construct in the pCMV-Myc vector was fully sequenced with the 
appropriate primers (Appendix III), as described in section 3.1.3.2. The LAP1B sequence 
obtained was analysed and the insert orientation into the pCMV-Myc vector and the 
reading frame confirmed. 
 
3.3.3.3. Validation of PP1/LAP1B interaction by co-immunoprecipitation 
 
In order to confirm the interaction of LAP1B with PP1 in vivo, co-
immunoprecipitation assays were carried out using cellular extracts obtained from COS-7 
cells transfected with Myc-LAP1B. Co-immunoprecipitations were performed using anti-
PP1γ, anti-PP1α or anti-Myc antibodies. Cells lysates and immunoprecipitates were 
separated by 10% SDS-PAGE and transferred to a nitrocellulose membrane, 
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4 Kb 
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immunoblotted with anti-Myc or anti-PP1γ antibodies and developed by ECL. Upon 
immunoprecipitation with PP1γ (Fig. 27A) and PP1α (Fig. 27A), a strong band below 75 
KDa, corresponding to Myc-LAP1B protein, could be detected by immunoblotting with 
anti-Myc antibody. This result indicates and confirms that Myc-LAP1B interacts with PP1 
isoforms α and γ. A non specific Protein A band of approximately 50 kDa was also 
detected in immunoprecipitates (Fig. 27A). Immunoblot analysis of COS-7 cell extracts 
immunoprecipitated with the anti-Myc antibody also demonstrated that LAP1B co-
immunoprecipitate with PP1γ (Fig. 27B), since a strong band at 37 kDa can be observed. 
 
 
 
 
Figure 27. Validation of PP1/LAP1B interaction in vivo by co-immunoprecipitation. A- Immunoblot 
analysis of COS-7 cells immunoprecipitated with anti-PP1γ or anti-PP1α antibody and immunoblotted with 
anti-Myc antibody.  Non-transfected (NT) cells and NT cells with Sepharose A (Seph. A) beads were used as 
controls. B- Immunoblot analysis of COS-7 cells immunoprecipitated with anti-Myc antibody and 
immunoblotted with anti-PP1γ antibody. NT cells and NT cells with Sepharose G (Seph. G) beads were used 
as controls. IP, immunoprecipitation. 
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3.3.4. Discussion 
 
Co-immunoprecipitation is a reliable technique used to validate in vivo protein 
interactions that works by formation of antigen-antibody complexes. To address the 
physiological relevance of PP1/LAP1B interaction we attempted to demonstrate complex 
formation between Myc-LAP1B and endogenous PP1γ and α isoforms in a mammalian 
cell line. Immunoprecipitations were performed from COS-7 cellular extracts transfected 
with Myc-LAP1B, using specific antibodies: anti-PP1γ, anti-PP1α or anti-Myc. 
Immunoprecipitation with both anti-PP1γ and anti-PP1α antibodies followed by 
immunoblot analysis using an antibody (anti-Myc) that recognizes the Myc-tag of the 
Myc-LAP1B fusion protein, showed that LAP1B interacts with both PP1 isoforms. 
Furthermore, immunoblot analysis using anti-PP1γ antibody after immunoprecipitation 
with anti-Myc antibody also demonstrated that LAP1B interacts with PP1γ. These results 
clearly show that LAP1B interacts in vivo with both PP1γ and α isoforms. These results are 
in agreement and further extend the results obtained in the previous sections, thus 
validating the physiological relevance of PP1/LAP1B interaction. 
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3.4. Co-localization of LAP1B with PP1 isoforms α and γ 
 
3.4.1. Introduction 
 
In order to evaluate if and where PP1 and LAP1B co-localize in mammalian cells, 
subcellular localization studies were carried out using HeLa cells. HeLa cells are an 
immortal cell line derived from human cervical cancer cells, and they are often used for co-
localization studies. The expression of the recombinant LAP1B fusion protein allows the 
analysis of its subcellular distribution and its co-localization with endogenous PP1 
isoforms by immunocytochemistry using specific antibodies. Transfection was carried out 
with polyethylenimine (PEI) that is a class of cationic polymers proven to be effective for 
gene delivery into a variety of cells. PEI is one of the most densely charged polymers and 
has the function of condensing DNA into small particles, which facilitates DNA cellular 
uptake via endocytosis (100). 
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3.4.2. Materials and methods 
 
3.4.2.1. Cell culture  
 
HeLa cells were grown in Minimal Essential Medium with Earle's salts and 
GlutaMAX (MEM, Gibco), supplemented with 10% fetal bovine serum (FBS; Gibco), 1% 
MEM Non-Essential amino acids (Gibco, Invitrogen) and 100 U/mL penicillin and 100 
mg/mL streptomycin (Gibco). Cultures were maintained at 37ºC and 5% CO2. Cells were 
subcultured whenever 90-95% confluency was reached. 
 
3.4.2.2. Transfection with polyethylenimine (PEI)  
 
HeLa Cells were grown in complete MEM until 90% confluency was reached and 
10 μg of recombinant plasmid DNA were diluted in 750 μL of NaCl (150 mM). The PEI 
solution (100 μL) was diluted in 650 μL of NaCl (150 mM) and the tubes were left for 15 
min at room temperature. The PEI solution was added to the DNA drop by drop. In order 
to form the DNA-PEI complexes, the tube was left for 15 min at room temperature. During 
this time the medium of the cells was removed and 2.5 ml of fresh complete MEM was 
added. The complexes were added to this medium, drop by drop and with gentle rocking of 
the plate. The cells were then incubated at 37ºC/5% CO2 for 5 hr. After that period the 
medium was replaced with fresh complete MEM and the cells were left to recover for 20 
hr. 
 
3.4.2.3. Immunocytochemistry procedure 
 
HeLa cells were grown in glass coverslips pre-coated with 100 g/mL poly-L-
ornithine. HeLa cells were cultured until 90% confluency was reached and transfected as 
described above. Each well was washed three times with 1mL serum-free MEM medium 
and then 1 mL of 1:1 MEM/4% paraformaldehyde fixative solution was gently added and 
left to stand for 2 min. Subsequently, 1 mL of fixative solution was gently added and left 
for 25 min. Finally, cells were washed three times with 1 mL 1x PBS for 10 min. For cell 
permeabilization, 1 mL of methanol was added for 2 min and then washed 5 times with 1 
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mL 1x PBS for 10 min. The coverslips were blocked for 1 hr with 3% BSA in 1x PBS, and 
then incubated with primary antibody for 2 hours at room temperature. After three washes 
with 1x PBS, the secondary antibody was added and the coverslips incubated for 2 hr. The 
antibodies were diluted in 3% BSA in 1x PBS. Finally, three washes with 1x PBS were 
performed and coverslips were mounted on microscope glass slides with 1 drop of anti-
fading reagent containing DAPI for nucleic acid staining (Vectashield, Vector 
Laboratories). Photographs were acquired using a LSM 510-Meta confocal microscope 
equipped with appropriate software (Zeiss).   
 
3.4.2.3.1. Antibodies  
 
The primary antibodies used were a monoclonal anti-Myc antibody (Cell Signaling, 
1:5000 dilution), a polyclonal anti-PP1α antibody (CBC2C, 1:5000 dilution), a polyclonal 
anti-PP1γ antibody (CBC3C, 1:1000 dilution) and a polyclonal anti-lamin A/C antibody 
(1:50 dilution). The secondary antibodies used were an anti-mouse fluorescein 
isothiocyanate (FITC) conjugated antibody (Molecular Probes, 1:50 dilution) and the anti-
rabbit Alexa Fluor 594 conjugated antibody (Molecular Probes, 1:300 dilution). The 
antibodies were diluted in 3% BSA in 1x PBS. 
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3.4.3. Results 
 
In order to address the physiological relevance of PP1/LAP1B interaction, we 
evaluated the subcellular distribution and co-localization of both proteins in HeLa cells. 
Hela cells were transfected with the Myc-LAP1B construct and the expression of the 
fusion protein allowed the analysis of its subcellular distribution and its co-localization 
with endogenous PP1 isoforms (α and γ) and also with lamin A/C. Myc-LAP1B expression 
was detected with anti-Myc antibody and an anti-mouse FITC conjugated secondary 
antibody. Confocal fluorescence microscopy analysis revealed that Myc-LAP1B was 
almost exclusively localized at the nuclear envelope (Fig. 28A and B). Figure 28A shows 
two examples of cells transfected with Myc-LAP1B and two non transfected cells, the 
latter can be clearly differentiated from the transfected cells by the lower background 
staining of the cytoplasm and the absence of nuclear envelope staining. Myc-LAP1B 
immunoreactivity was also detected in some type of subnuclear structures (Fig. 28A and B, 
arrows). 
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Figure 28. Subcellular distribution of Myc-LAP1B in HeLa cells. Myc-LAP1B was detected using an anti-
mouse FITC conjugated secondary antibody (green). Nucleic acids were stained using DAPI (blue). Co-
localization of Myc-LAP1B and DAPI staining can be observed in the merge figure. A- Two HeLa cells 
transfected with the Myc-LAP1B construct showing nuclear envelope immunoreactivity. Two non 
transfected cells are also observed. B- Nuclear envelope distribution of exogenous Myc-LAP1B. Myc-
LAP1B immunoreactivity is also observed in subnuclear structures (arrows). Bar, 10 μm. 
 
 
Given the apparent nuclear envelope distribution of LAP1B, co-localization 
analysis of LAP1B with an endogenous nuclear envelope marker was also carried out to 
confirm its subcellular distribution. Thus, lamin A/C was used since this protein is well 
known to associate with LAP1B and is a typical nuclear envelope marker. Localization of 
endogenous lamin A/C was performed using an anti-lamin A/C antibody and detected with 
an anti-rabbit Alexa Fluor 594 conjugated secondary antibody. As expected, endogenous 
lamin A/C was almost exclusively distributed in the nuclear envelope where it co-localizes 
extensively with Myc-LAP1B (Fig. 29). 
  
A  
B  
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Figure 29. Co-localization of Myc-LAP1B and endogenous lamin A/C. Myc-LAP1B was detected with an 
anti-mouse FITC conjugated secondary antibody (green). Lamin A/C was detected with an anti-rabbit Alexa 
Fluor 594 conjugated secondary antibody (red). Nucleic acids were stained using DAPI (blue). The nuclear 
envelope co-localization of Myc-LAP1B and lamin A/C can be clearly seen in the merge figure. Bar, 10 μm. 
 
 
Since PP1 isoforms are particularly enriched within the nucleus, we also evaluated 
the co-localization of LAP1B with and endogenous PP1 isoforms (α and γ). Endogenous 
PP1α and PP1γ were labeled with specific anti-PP1α or anti-PP1γ antibodies, respectively, 
and detected with an anti-rabbit Alexa Fluor 594 conjugated secondary antibody. 
Endogenous PP1γ (Fig. 30A) and PP1α (Fig. 30B) were found mainly in the nucleus but 
some immunoreactivity in the cytoplasm was also observed. In the nucleus, PP1γ was 
found within the nucleolar like structures (Fig. 30A), from which PP1α was excluded (Fig. 
30B). Co-localization of Myc-LAP1B with PP1γ (Fig. 30A and A’) and PP1α (Fig. 30B 
and B’) was observed at several subnuclear structures and at points near the nuclear 
envelope. The co-localization of Myc-LAP1B and PP1α in specific points (Fig. 30C, 
arrow) was validated by the overlap between the green fluorescence intensity (FITC 
conjugated secondary antibody labelling Myc-LAP1B) and the red fluorescence intensity 
(Alexa Fluor 594 conjugated secondary antibody labelling PP1α), represented in the 
histogram (Fig. 30C’). 
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Figure 30. Co-localization of Myc-LAP1B and PP1 in HeLa cells. A- Co-localization of Myc-LAP1B with 
endogenous PP1γ. B- Co-localization of Myc-LAP1B with endogenous PP1α. A’- Amplified image of A – 
Merge. B’- Amplified image of B - Merge. Expressed Myc-LAP1B was detected with an anti-mouse FITC 
conjugated secondary antibody (green). Nucleic acids were stained using DAPI (blue). Endogenous PP1γ and 
PP1α were detected with an anti-rabbit Alexa Fluor 594 conjugated secondary antibody (red). The co-
localization of Myc-LAP1B and PP1 isoforms can be observed in the merge figure (yellow/orange, arrows). 
C- Co-localization of Myc-LAP1B with endogenous PP1α in specific points (arrow). C’- Histogram 
representing the green fluorescence intensity (FITC conjugated secondary antibody labelling Myc-LAP1B) 
and the red fluorescence intensity (Alexa Fluor 594 conjugated secondary antibody labelling PP1α) in a 
specific distance (arrow from C). Bar, 10 μm. 
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3.4.4. Discussion 
 
The simultaneous presence of two proteins in the same subcellular compartments is 
a condition for in vivo interaction. However, they might come in contact with each other in 
the cytoplasm as the protein is translated or in another location. Therefore it is important to 
determine the subcellular distribution of these proteins and the specific structures with 
which they are associated. The subcellular distribution and co-localization between PP1 
and Myc-LAP1B were evaluated in HeLa cells by immunocytochemistry. Myc-LAP1B 
exhibited nuclear envelope localization as previously reported (89). To confirm its nuclear 
envelope distribution, the co-localization of Myc-LAP1B with lamin A/C, a marker for the 
nuclear envelope, was evaluated. LAP1B binds both lamins A and C and lamin B (83), 
which are the main components of the nuclear lamina. As expected, co-localization at the 
nuclear envelope between LAP1B and lamin A/C was clearly observed. Endogenous PP1γ 
and PP1α were found enriched in the nucleus of HeLa cells. Within the nucleus, whereas 
PP1γ was found enriched in nucleolar like structures, PP1α was apparently excluded from 
those structures. Co-localization of endogenous PP1γ and PP1α with Myc-LAP1B was 
observed at several sites other than the nucleus but, since no specific antibodies for these 
structures were available, it was not possible to unequivocally identify those structures. 
Further work will be required to accomplish the identification of these structures. Co-
localization of LAP1B and PP1 was also seen at some points near the nuclear envelope, in 
agreement with putative interaction through the nucleoplasmic portion of LAP1B.  
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4. Discussion 
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PP1 is the most widely expressed and abundant protein serine/threonine 
phosphatase. PP1 is involved in many cellular processes like glycogen metabolism, 
transcription, protein synthesis, cellular division, meiosis and apoptosis (reviewed in 8).  
Furthermore, abnormal protein phosphorylation has been associated with several 
neurodegenerative diseases, such as AD, where PP1 is involved. This versatility of PP1 is 
only possible by complexing with numerous regulatory subunits, which confer distinct 
substrate specificity, activity and targeting to a particular subcellular localization (9, 17). 
For instance, PP1 is enriched in dendritic spines in brain (34) and this observation led to 
the discovery of spinophilin, which binds PP1 and targets it to the post-synaptic density. 
The three PP1 isoforms α, β and γ1 are widely expressed in brain and their mRNA is 
particularly abundant in hippocampus and cerebellum. At the protein level PP1α and 
PP1γ1 are enriched within the striatum (29).  
Given the abundance of PP1 isoforms in brain and the numerous functions that 
have been associated with PP1 via its binding subunits, a yeast two-hybrid screen of a 
human brain cDNA library was performed using PP1 isoforms α, γ1 and γ2 and as bait, in 
order to identify novel PP1 interacting proteins in brain. Among several interesting 
proteins, LAP1B/TOR1AIP1 was identified as a novel putative PP1 regulator. Overall, 
fourteen, four and two positive clones encoding for LAP1B were identified using PP1α, 
PP1γ1 and PP1γ2 and as bait, respectively. We decided to further evaluate LAP1B given 
that LAP1B binds to TorsinA (67), a protein involved in EOTD. Most cases of EOTD are 
associated with an in-frame three bp deletion (∆GAG) in the DYT1 gene, leading to loss of 
a single glutamic acid residue at position 302 or 303 (∆E302/303) within torsinA (44). As 
other AAA
+
 ATPases, torsinA may act as a chaperone, working at several subcellular 
compartments through interaction with different binding partners, including the 
transmembrane proteins LAP1B in the NE and LULL1 in the ER (67, 68), KLC1 in the 
cytoplasm (70) and vimentin (71) and snapin on dense core granules (77). Subcellular 
studies demonstrated that Wt-torsinA is found in the ER (60, 62) and, upon over-
expression, is also found in the NE (64, 65), while mutant torsinA is located mainly in the 
NE (67). Given that LAP1B is an inner nuclear membrane protein and interacts through its 
lumenal domain with torsinA, the redistribution of mutant torsinA to the NE suggests that 
impaired interaction of torsinA with LAP1B may contribute to the development of EOTD 
(67, 101). Additionally, our results also indicate that LAP1B interacts with PP1, so a new 
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perspective for the study of EOTD is open, where PP1 and/or abnormal protein 
phosphorylation might represent a pivotal event.  
In order to obtain more information on LAP1B and its putative functions, we 
performed a bioinformatics analysis of its amino acid sequence. First, all LAP1B clones 
obtained in the YTH screen were sequenced, and their analysis verified that all were a 
variant of LAP1B sequence reported in the NCBI database (NM_015602). These clones 
include 3 more nucleotides (CAG) which result in the inclusion of a single alanine at 
position 185 of the LAP1B coding sequence. This sequence is identical to that reported by 
Kondo et al (2002) (89). Indeed, the inclusion/exclusion of three nucleotides (CAG) is 
very common among other proteins and in some reported this subtle alternative splicing 
may even affect the subcellular localization of such variants (102). Furthermore, expansion 
of CAG repeats in the coding region characterizes some neurodegenerative diseases, like 
Huntington’s disease. For further study, we chose clone 135 (for the PP1γ1 YTH screen) 
that encodes for the full-length LAP1B. Bioinformatics analysis revealed that LAP1B 
possesses three well conserved PP1 binding motifs and a second generic PP1 binding motif 
named SILK, indicating the strong possibility that LAP1B interacts with PP1. LAP1B also 
possesses several potential phosphorylation sites for, for example, CK1, CK2, GSK3 and 
PLK. LAP1B can be both a substrate for PP1 and/or a targeting protein that directs PP1 to 
a specific subcellular compartment, where PP1 may dephosphorylate another protein. 
Therefore, we are particularly interested in characterizing the PP1/LAP1B complex.  
The PP1/LAP1B interaction was further confirmed using several methodologies. 
First, by taking advantage of the YTH system, LAP1B and PP1 isoforms were co-
transformed in yeast. Results showed that LAP1B interacts with PP1α, PP1γ1 and PP1γ2. 
These results are in agreement with the fact that positive clones encoding LAP1B were 
identified in all three YTH screens, using specifically these PP1 isoforms as bait. 
Furthermore, the LAP1B deletion mutants (cloned into pACT2 vector) indicated that the 
LAP1B interaction with PP1γ1 occur primarily through BM1. These results are consistent 
with BM1 being located in the nucleoplasmic portion of LAP1B and PP1 being 
particularly abundant in the nucleus. As expected, construct BM1/2 also interacts with 
PP1γ1, since it also possesses BM1. To analyse the PP1/LAP1B interaction in vitro, we 
cloned LAP1B into the pET-28c vector and expressed the recombinant protein in bacteria 
and performed a blot overlay assay using purified PP1γ1 protein. The results obtained 
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confirmed the direct interaction between LAP1B and PP1γ1. Using the deletion mutants 
(also cloned into the pET-28c vector), we also confirmed that PP1γ1 binds BM1/2, in 
agreement with the yeast-co-transformation results. In order to address the PP1/LAP1B 
interaction in vivo, we performed either co-immunoprecipitation with PP1α or PP1γ 
antibodies followed by detection with Myc-LAP1B using Myc antibody, or co-
immunoprecipitation with the Myc antibody and detection of PP1γ using the PP1γ specific 
antibody. These experiments showed that PP1 and LAP1B form a complex in vivo, thus 
validating the physiological relevance of the PP1/LAP1B complex. The co-localization of 
PP1 and Myc-LAP1B were evaluated in a human cell line (HeLa cells). As expected, 
endogenous PP1γ and PP1α were enriched within the nucleus and Myc-LAP1B was 
distributed mainly around the nuclear envelope. Co-localization of Myc-LAP1B and PP1γ 
or PP1α was observed at several locations near the nuclear envelope and in unidentified 
subnuclear structures. Thus, further work is required to identify the nature of such 
structures, where PP1 and LAP1B may interact. To evaluate the physiological relevance of 
the PP1/LAP1B complex, subcellular studies in primary neuronal cultures and co-
immunoprecipitation from specific brain regions, particularly from striatum and 
cerebellum (the more important regions for EOTD) also need to be performed. The 
validation of a putative PP1/LAP1B/torsinA trimeric complex (Fig. 31) and its relevance 
for EOTD needs to be fully evaluated.  
The functional role of LAP1B is poorly understood but it is known that LAP1B 
interacts with lamins and chromosomes, which may be important for the maintenance of 
the nuclear architecture (89). Moreover lamins are phosphorylated during 
prophase/metaphase and dephosphorylated at telophase when the NE is reassembled, and 
this may be determined by the association of lamins with other proteins such as LAPs (79) 
and PP1 (84). LAP1 and LAP2 dissociate from the lamins at the onset of mitosis and 
associate before the reassembly of the nuclear lamina. Furthermore, LAP1 and LAP2 are 
phosphorylated during mitosis and hyperphosphorylation of LAP2 inhibits binding to 
lamin B1 and chromosomes. However, mitotic phosphorylation of LAP1 does not 
detectably alter the binding to lamins in vitro (83). Furthermore, it was proposed that PP1 
mediates nuclear lamina reassembly, in part by dephosphorylation of lamin B (85), and 
AKAP-149 recruits PP1 to the NE upon NE assembly in vitro and promotes lamin B 
dephosphorylation and polymerization (86). Given that LAP1B associates with lamin B 
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and that AKAP-149/PP1 complex is involved in lamin B dephosphorylation, LAP1B may 
target PP1 to lamin B. PP1 and LAP1B may be involved in regulating NE reassembly and 
lamin B association to the NE.  
Interestingly, the identification of LAP1B as a PP1 binding protein opens new 
perspectives for the study of EOTD, where protein phosphorylation may constitute a 
pivotal regulatory mechanism. Like LAP1B, torsinA also possesses potential sites for 
phosphorylation. Since PP1 interacts with LAP1B through its nucleoplasmic domain and 
torsinA interacts with the lumenal domain of LAP1B (Fig. 31), it will be interesting to 
evaluate the occurrence of a trimeric PP1/LAP1B/torsinA complex and to unravel its 
functional relevance for EOTD.  
 
 
 
 
Figure 31. Schematic illustration of the putative PP1/LAP1B/TorsinA tricomplex. LAP1B interacts with the 
PP1c (PP1 catalytic subunit) in the nucleoplasm through the PP1 binding motif BM1. TorsinA can be found 
in the perinuclear space where it interacts with the lumenal domain of LAP1B. BM1, PP1 binding motif 1; 
SILK, a second generic PP1 binding motif; TM, transmembrane domain; SP, signal peptide; NLS, nuclear 
localization signal, INM, inner nuclear membrane, ONM, outer nuclear membrane. 
 
 
TorsinA mRNA is widely distributed throughout all brain regions with higher 
expression in the dopaminergic neurons of the substantia nigra pars compacta (50, 51). The 
higher expression of torsinA within the substantia nigra pars compacta, which provides 
dopaminergic innervations to the basal ganglia, implicates a disturbance of dopaminergic 
function in the pathophysiology of EOTD (50). PP1 isoforms are highly expressed in brain 
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and PP1γ1 and PP1α are particularly enriched within the striatum. Here PP1 is involved in 
the action of several neurotransmitters, like dopamine and glutamate, via regulation by 
DARPP-32. Thus, it is believed that PP1 may play a role in dopaminergic signal 
transduction (34). Given the high expression levels of PP1 isoforms within the striatum, 
and the relationship between basal ganglia dopaminergic signalling and EOTD, the 
hypothesis that PP1 and/or abnormal protein phosphorylation may have a role in EOTD 
seems worthwhile exploring in the future. 
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I. Culture media and solutions 
 
Bacteria media 
  
LB (Luria-Bertani) Medium 
 
To 950 mL of deionised H2O add: 
LB 25 g 
Agar 15 g (for plates only) 
Shake until the solutes have dissolved. Adjust the volume of the solution to 1 L 
with deionised H2O. Sterilize by autoclaving. 
 
SOB Medium 
 
To 950 mL of deionised H2O add: 
SOB Broth 25.5 g 
Shake until the solutes have dissolved. Add 10 mL of a 250mM KCl (prepared by 
dissolving 1.86g of KCl in 100 mL of deionised H2O). Adjust the pH to 7.0 with 5N 
NaOH. Just prior to use add 5 mL of a sterile solution of 2M MgCl2 (prepared by 
dissolving 19 g of MgCl2 in 90 mL of deionised H2O). Adjust the volume of the solution to 
1 L with deionised H2O and sterilize by autoclaving). 
 
SOC Medium 
 
SOC is identical to SOB except that it contains 20 mM glucose. After the SOB 
medium has been autoclaved, allow it to cool to 60ºC and add 20 mL of a sterile 1M 
glucose (this solution is made by dissolving 18 g of glucose in 90 mL of deionised H2O; 
after the sugar has dissolved, adjust the volume of the solution to 1 L with deionised H2O 
and sterilize by filtration through a 0.22-micron filter). 
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Antibiotics (1000x) 
 
Ampicilin 100 μg/μL  
Kanamycin 30 μg/μL   
 
Competent Cell Solutions 
 
Solution I (1L) 
 
MnCl2.4H2O 9.9 g 
CaCl2.2H2O 1.5 g 
Glycerol 150 g 
KHAc 1M  30 mL 
Adjust the volume of the solution to 1 L with deionised H2O. Adjust pH to 5.8, 
filter through a 0.2 μm filter and store at 4ºC 
 
Solution II (1L) 
 
0.5M MOPS (pH 6.8) 20 mL 
RbCl 1.2 g 
CaCl2.2H2O 11g 
Glycerol  150 g  
Adjust the volume of the solution to 1 L with deionised H2O. Filter through a 0.2 
μm filter and store at 4ºC  
 
DNA electrophoresis solutions 
 
50x TAE Buffer  
 
Tris base  242 g 
Glacial acetic acid 57.1 mL 
0.5M EDTA (pH 8.0) 100 mL 
 Validation of LAP1B as a novel PP1 regulator 
 
Mestrado em Biologia Molecular e Celular 108 
 
Loading Buffer (LB) 
 
Bromophenol blue 0.25% 
Glycerol  30%  
 
Midiprep Solutions 
  
Cell Resuspension Solution 
 
50 mM Tris-HCl (pH 7.5) 
10 mM EDTA 
100 µg/mL RNAase A  
 
Cell Lysis Solution  
 
0.2 M NaOH 
1% SDS 
 
Neutralization Solution 
 
4.09 M Guanidine hydrochloride (pH 4.8) 
759 mM potassium acetate  
2.12 M Glacial acetic acid 
 
Column Wash Solution 
 
60 mM potassium acetate 
8.3 mM Tris-HCl (pH 7.5) 
0.04 mM EDTA 
60 % ethanol 
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Yeast Media 
 
10x Dropout solution (10x DO) 
 
This solution contains all but one or more of the following components: 
 
             10x concentration (mg/L)    SIGMA # 
L-Isoleucine     300       I-7383 
L-Valine     1500      V-0500 
L-Adenine hemisulfate salt   200      A-9126 
L-Arginine HCl    200      A-5131 
L-Histidine HCl monohydrate  200      H-9511 
L-Leucine     1000      L-1512 
L-Lysine HCl     300      L-1262 
L-Methionine     200      M-9625 
L-Phenylalanine    500      P-5030 
L-Threonine     2000      T-8625 
L-Tryptophan                200      T-0254 
L-Tyrosine     300      T-3754 
L-Uracil     200      U-0750 
 
10x dropout supplements may be autoclaved and stored for up to 1 year. 
 
Triple Drop Out: DO/-Leu/-Trp/-His 
Quadruple Drop Out: DO/-Leu/-Trp/-His/-Ade 
 
YPD medium 
 
To 950 mL of deionised H2O add:  
YPD 50 g 
Agar 15 g (for plates only) 
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Shake until the solutes have dissolved. Adjust the volume to 1 L with deionised 
H2O and sterilize by autoclaving. Allow medium to cool to 60ºC and add glucose to 2% 
(50 mL of a sterile 40% stock solution).  
 
SD synthetic medium 
 
To 800 mL of deionised H2O add:  
Yeast nitrogen base without amino acids (DIFCO) 6.7 g 
Agar (for plates only)     15 g 
Shake until the solutes have dissolved. Adjust the volume to 850mL with deionised 
H2O and sterilize by autoclaving. Allow medium to cool to 60ºC and add glucose to 2% 
(50 mL of a sterile 40% stock solution) and 100 mL of the appropriate 10x dropout 
solution. 
 
TE Buffer (pH 7.5) 
 
10 mM Tris-HCl (pH 7.5) 
1 mM EDTA (pH 8.0) 
 
SDS-PAGE and Immunoblotting Solutions  
 
LGB (Lower Gel Buffer) 
 
To 900 mL of deionised H2O add:  
Tris 181.65 g 
SDS  4 g  
Mix until the solutes have dissolved. Adjust the pH to 8.9 and adjust the volume to 
1 L with deionised H2O. 
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UGB (Upper Gel Buffer) 
  
To 900 mL of deionised H2O add:  
Tris 75.69 g 
Mix until the solute has dissolved. Adjust the pH to 6.8 and adjust the volume to    
1 L with deionised H2O. 
 
30% Acrylamide/0.8% Bisacrylamide 
 
To 70 mL of deionised H2O add: 
Acrylamide 29.2 g 
Bisacrylamide 0.8 g 
Mix until the solutes have dissolved. Adjust the volume to 100 mL with deionised 
H2O. Filter through a 0.2 μm filter and store at 4°C. 
 
10% APS (ammonium persulfate) 
 
In 10 mL of deonised H2O dissolve 1 g of APS.  
 
10% SDS (sodium dodecilsulfate) 
 
In 10 mL of deonised H2O dissolve 1 g of SDS. 
 
Loading Gel Buffer (4x) 
 
1 M Tris solution (pH 6.8) 2.5 ml (250 mM) 
SDS    0.8 g (8%) 
Glycerol   4 mL (40%) 
β-Mercaptoethanol  2 mL (2%) 
Bromophenol blue  1 mg (0.01 %) 
Adjust the volume to 10 mL with deionised H2O. Store in darkness at room 
temperature. 
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1 M Tris (pH 6.8) solution 
 
To 150 mL of deonised H2O add: 
Tris base 30.3 g 
Adjust the pH to 6.8 and adjust the final volume to 250 mL. 
 
10x Running Buffer  
 
Tris  30.3 g (250 mM)  
Glycine 144.2 g (2.5 M) 
SDS  10 g (1%) 
Dissolve in deionised H2O, adjust the pH to 8.3 and adjust the volume to 1 L. 
 
1x Transfer buffer  
 
Tris  3.03 g (25 mM) 
Glycine 14.41 g (192 mM) 
Mix until solutes dissolution. Adjust the pH to 8.3 with HCl and adjust the volume 
to 800 mL with deionised H2O. Just prior to use add 200 mL of methanol (20%). 
 
10x TBS (Tris buffered saline) 
 
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O.  
 
10x TBST (TBS + Tween) 
 
Tris  12.11 g (10 mM) 
NaCl  87.66 g (150 mM) 
Tween 20 5 mL (0.05 %) 
Adjust the pH to 8.0 with HCl and adjust the volume to 1 L with deionised H2O.  
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Coomassie blue staining solutions 
 
Staining solution 
 
Coomassie Brilliant Blue 2 g 
Methanol   500 mL 
Acetic Acid   100 mL 
Adjust the volume to 1 L with deionised H2O. 
 
Destaining solution 
 
Methanol 250 mL 
Acetic Acid 50 mL 
Adjust the volume to 1 L with deionised H2O. 
 
Cell Culture Solutions and Immunocytochemistry  
 
1x PBS 
 
For a final volume of 500 mL, dissolve one pack of BupH Modified Dulbecco’s 
Phosphate Buffered Saline Pack (Pierce) in deionised H2O. Final composition: 
8 mM Sodium Phosphate   
2 mM Potassium Phosphate  
40 mM NaCl  
10 mM KCl  
Sterilize by filtering through a 0.2 m filter and store at 4ºC 
 
1 mg/mL Poly-L-ornithine solution (10x) 
 
To a final volume of 100 mL, dissolve in deionised H2O 100 mg of poly-L-
ornithine (Sigma-Aldrich, Portugal).  
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4% Paraformaldehyde  
 
For a final volume of 100 mL, add 4 g of paraformaldehyde to 25 mL deionised 
H2O. Dissolve by heating the mixture at 58ºC while stirring. Add 1-2 drops of 1 M NaOH 
to clarify the solution and filter (0.2 m filter). Add 50 mL of 2X PBS and adjust the 
volume to 100 mL with deionised H2O. 
 
Complete MEM + GLUTAMAX (HeLa cells) 
 
For a final volume of 500 mL, add:  
Fetal Bovine Serum (FBS) (Gibco BRL, Invitrogen) 50 mL (10% v/v) 
Non-Essential aminoacids (1% v/v)    5 mL 
Penicillin       100 U/mL 
Streptomycin (100 mg/mL)     5 mL 
FBS is heat-inactivated for 30 min at 56ºC. For cell maintenance, prior to pH 
adjustment add 100 U/mL penicillin and 100 mg/mL streptomycin [10 mL Streptomycin/ 
Penicilin/Amphotericin solution (Gibco BRL, Invitrogen) 
 
MEM + GLUTAMAX Components     
 
Amino Acids:                                     Concentration (mg/L) 
L-Alanyl-Glutamine           406 
L-Arginine hydrochloride           126 
L-Cystine           24 
L-Histidine hydrochloride           42 
L-Isoleucine           52 
L-Leucine           52 
L-Lysine hydrochloride           73 
L-Methionine           15 
L-Phenylalanine           32 
L-Threonine           48 
L-Tyrosine           10 
L-Valine           46 
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Vitamins: 
Choline chloride           1 
D-Calcium pantothenate           1 
Folic Acid           1 
Niacinamide           1 
Riboflavin           0.1 
Thiamine hydrochloride           1 
i-Inositol           2 
Inorganic Salts: 
Calcium Chloride (CaCl2.2H2O)           264 
Magnesium Sulfate (MgSO4.7H2O)           200 
Potassium Chloride           400 
Sodium Bicarbonate           2200 
Sodium Chloride           6800 
Sodium Phosphate monobasic 
(NaH2PO4.2H2O) 
          158 
Other components: 
D-Glucose           1000 
Phenol Red           10 
 
DMEM medium (COS-7 cells) 
 
For a final volume of 1 L, dissolve one pack of DMEM powder (with L-glutamine 
and 4500 mg glucose/L, Sigma Aldrich) in deionised H20 and add: 
NaHCO3 (Sigma-Aldrich) 3.7 g 
Adjust the pH 7.4. Sterilize by filtering through a 0.2 μm filter and store at 4°C. 
 
Complete DMEM (COS-7 cells) 
 
For a final volume of 1 L, when preparing DMEM medium adjust to pH 7.4 and 
before sterilizing add: 
Fetal bovine Serum (FBS) (Gibco BRL, Invitrogen) 100 mL (10% v/v) 
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Notes: FBS is heat-inactivated for 30 min at 56°C. For cell maintenance, prior to pH 
adjustment add 100 U/mL penicillin and 100 mg/mL streptomycin (100 mL 
Streptomycin/Penicilin/Amphotericin solution (Gibco BRL, Invitrogen)). 
 
Polyethylenimine (PEI) solution 
 
For a final volume of 10 mL, add 9 mg of PEI to deionised H20. Dissolve by 
vortexing. Sterilize by filtration.  
 
Immunoprecipitation solutions 
 
Lysis Buffer 
 
50 mM Tris-HCl (pH 8) 1 mL  
120 mM NaCl   2.4 mL 
4% CHAPS   0.8 g 
Adjust the volume to 20 mL with deionised H2O. 
 
Lysis Buffer + Protease inhibitors 
 
Add to 4 mL of Lysis buffer the following quantities for a final volume of 5 mL: 
Pepstatin A (1 mg/mL stock solution in DMSO) 23.8 µL  
Leupeptin (5 mg/mL stock solution)   0.72 µL 
Benzamidine (200 mM stock solution)  180 µL 
Aprotinin (2,1 mg/mL stock solution)  43.2 L 
PMSF (10 mM stock solution)   176 µL 
 
Washing solution 
 
50 mM Tris-HCl 2.5 mL  
120 mM NaCl  6 mL 
Adjust the volume to 50 mL with deionised H2O.  
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II. Plasmids 
 
 
 
 
 
 
pACT2 (Clontech) map and multiple cloning sites. Unique sites are in bold. pACT2 is used to generate a 
hybrid containing the GAL4 AD, an epitope tag and a protein encoded by a cDNA in a fusion library. The 
hybrid protein is expressed at medium levels in yeast host cells from an enhanced, truncated ADH1 promoter 
and is targeted to the nucleus by the SV40 T-antigen nuclear localization sequence. pACT2 contains the 
LEU2 gene for selection in Leu
-
 auxotrophic yeast strains. 
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pAS2-1 (Clontech) map and multiple cloning sites. Unique restriction  sites are coloured blue. pAS2-1 is a 
cloning vector used to generate fusions of a bait protein with the GAL4 DNA-BD. The hybrid protein is 
expressed at high levels in yeast host cells from the full-length ADH1 promoter. The hybrid protein is 
targeted to the yeast nucleus by nuclear localization sequences. pAS2-1 contains the TRP1 gene for selection 
in Trp
-
 auxotrophic yeast strains. 
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pCMV-Myc (Clontech) restriction map and multiple cloning sites. Unique restriction sites are in bold. 
pCMV-Myc is a mammalian expression vector with an N-terminal c-Myc epitope tag. This vector possesses 
the ampicillin resistance gene for selection in E. coli. 
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pET-28a-c(+) (Novagen) restriction map and multiple cloning sites. Unique sites are indicated on the 
circular map. pET-28a-c(+) is a E. coli expression vector with an N-terminal His tag/thrombin/T7 tag. This 
vector possesses the Kanamycin resistance gene.  
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III. Primers 
 
 
 
Primer Sequence 5’ --- 3’ MT °C 
Gal4-AD, FW TACCACTACAATGGATG 48 
Amplimer 3, RV ATCGTAGATACTGAAAAACCCCGCAAGTTCAC 84 
T7 promoter TAATACGACTCACTATAGGG 56 
TOR1AIP1 cds, FW GGAATTCATATGGCGGGCGACGGG 69 
TOR1AIP1 cds, RV CCTCGAGTTATAAGCAGATGCCCCT 60 
TOR1AIP1 BM1, RV CCGCTCGAGTTAGACACTGGTGGCTTC 66 
TOR1AIP1 BM2, FW GGAATTCATATGGACGAGCCGCCAGAA 67 
TOR1AIP1 BM2, RV CCGCTCGAGTTAGGCTACATCTTTGAAGGC 67 
TOR1AIP1 BM3, FW GGAATTCATATGGCCAGATCCAGGGAT 64 
TOR1AIP1 681 CATTCCTCTGAAGAGGATG 55 
TOR1AIP1 1356 CAAGGTCAAGATGAGAAGCTG 58 
 
 
 
